0000862668-22-000026.txt : 20221114 0000862668-22-000026.hdr.sgml : 20221114 20221114160043 ACCESSION NUMBER: 0000862668-22-000026 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221114 DATE AS OF CHANGE: 20221114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ESCALON MEDICAL CORP CENTRAL INDEX KEY: 0000862668 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 330272839 STATE OF INCORPORATION: PA FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-20127 FILM NUMBER: 221384805 BUSINESS ADDRESS: STREET 1: 435 DEVON PARK ROAD STREET 2: SUITE 824 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 6106886830 MAIL ADDRESS: STREET 1: 435 DEVON PARK ROAD STREET 2: SUITE 824 CITY: WAYNE STATE: PA ZIP: 19087 FORMER COMPANY: FORMER CONFORMED NAME: INTELLIGENT SURGICAL LASERS INC DATE OF NAME CHANGE: 19930328 10-Q 1 esmc-20220930.htm 10-Q esmc-20220930
Escalon Medical Corp.00008626686/3010-QTRUE9/30/20222023Q1FALSEtruefalsefalse7,415,329FALSE000-201270.0010.00135,000,00035,000,0007,415,3297,415,3297,415,3297,415,3290.0010.0012,000,0002,000,0002,000,0002,000,00000008626682022-07-012022-09-3000008626682022-11-10xbrli:shares00008626682022-09-30iso4217:USD00008626682022-06-300000862668us-gaap:SecuredDebtMember2022-09-300000862668us-gaap:SecuredDebtMember2022-06-30iso4217:USDxbrli:shares0000862668us-gaap:ProductMember2022-07-012022-09-300000862668us-gaap:ProductMember2021-07-012021-09-300000862668us-gaap:ServiceMember2022-07-012022-09-300000862668us-gaap:ServiceMember2021-07-012021-09-3000008626682021-07-012021-09-300000862668us-gaap:PreferredStockMember2022-06-300000862668us-gaap:CommonStockMember2022-06-300000862668us-gaap:AdditionalPaidInCapitalMember2022-06-300000862668us-gaap:RetainedEarningsMember2022-06-300000862668us-gaap:PreferredStockMember2022-07-012022-09-300000862668us-gaap:CommonStockMember2022-07-012022-09-300000862668us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000862668us-gaap:RetainedEarningsMember2022-07-012022-09-300000862668us-gaap:PreferredStockMember2022-09-300000862668us-gaap:CommonStockMember2022-09-300000862668us-gaap:AdditionalPaidInCapitalMember2022-09-300000862668us-gaap:RetainedEarningsMember2022-09-300000862668us-gaap:PreferredStockMember2021-06-300000862668us-gaap:CommonStockMember2021-06-300000862668us-gaap:AdditionalPaidInCapitalMember2021-06-300000862668us-gaap:RetainedEarningsMember2021-06-3000008626682021-06-300000862668us-gaap:PreferredStockMember2021-07-012021-09-300000862668us-gaap:CommonStockMember2021-07-012021-09-300000862668us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000862668us-gaap:RetainedEarningsMember2021-07-012021-09-300000862668us-gaap:PreferredStockMember2021-09-300000862668us-gaap:CommonStockMember2021-09-300000862668us-gaap:AdditionalPaidInCapitalMember2021-09-300000862668us-gaap:RetainedEarningsMember2021-09-3000008626682021-09-3000008626682022-12-3100008626682022-07-012023-06-300000862668us-gaap:ConvertiblePreferredStockMember2022-07-012022-09-300000862668us-gaap:ConvertiblePreferredStockMember2021-07-012021-09-300000862668us-gaap:StockOptionMember2022-07-012022-09-300000862668us-gaap:StockOptionMember2021-07-012021-09-3000008626682018-02-14xbrli:pure00008626682021-07-012021-12-310000862668us-gaap:NotesPayableToBanksMember2018-06-290000862668us-gaap:NotesPayableToBanksMember2022-07-012022-12-310000862668esmc:PayrollProtectionProgramLoanMember2022-03-310000862668us-gaap:SecuredDebtMember2022-09-300000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300000862668esmc:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300000862668esmc:AccountsReceivableBenchmarkMember2022-07-012022-09-300000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-07-012022-09-300000862668us-gaap:AccountsReceivableMember2021-07-012022-06-300000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2021-07-012022-06-300000862668us-gaap:AccountsReceivableMember2022-07-012022-09-300000862668esmc:SupplieroneMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300000862668us-gaap:AccountsReceivableMember2021-07-012021-09-300000862668esmc:SupplieroneMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-300000862668us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberesmc:SupplierTwoMember2021-07-012021-09-300000862668us-gaap:SupplierConcentrationRiskMemberesmc:SupplierthreeMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-300000862668esmc:AccountsPayableBenchmarkMemberus-gaap:SupplierConcentrationRiskMember2022-07-012022-09-300000862668esmc:SupplieroneMemberesmc:AccountsPayableBenchmarkMemberus-gaap:SupplierConcentrationRiskMember2022-07-012022-09-300000862668esmc:AccountsPayableBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberesmc:SupplierTwoMember2022-07-012022-09-300000862668esmc:AccountsPayableBenchmarkMemberus-gaap:SupplierConcentrationRiskMember2021-07-012021-12-310000862668esmc:SupplieroneMemberesmc:AccountsPayableBenchmarkMemberus-gaap:SupplierConcentrationRiskMember2021-07-012022-06-300000862668country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300000862668country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-300000862668country:USus-gaap:GeographicConcentrationRiskMember2021-07-012021-09-300000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberus-gaap:NonUsMember2022-07-012022-09-300000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberus-gaap:NonUsMember2021-07-012021-09-300000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300000862668us-gaap:GeographicConcentrationRiskMember2021-07-012021-09-300000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-3000008626682023-06-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


 FORM 10-Q
QUARTERLY PERIOD PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934


For the Quarterly Period ended September 30, 2022
Commission File Number 0-20127


Escalon Medical Corp.
(Exact name of registrant as specified in its charter)

Pennsylvania 33-0272839
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
435 Devon Park Drive, Suite 824, Wayne, PA 19087
(Address of principal executive offices, including zip code)
(610) 688-6830
(Registrant’s telephone number, including area code)


N/A
Former name, former address and former fiscal year, if changed since last report
Securities registered pursuant to Section 12(b) of the Act: NONE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company. or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 


Large accelerated fileroAccelerated filero
Non-accelerated filer
x
Smaller reporting companyx
Emerging growth companyo

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  o    No  x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 7,415,329 shares of common stock, $0.001 par value, outstanding as of November 10, 2022.




TABLE OF CONTENTS
  Page
PART I Financial Information
Item I.
Unaudited Condensed Consolidated Financial Statements
Item 2.
Item 3.
Item 4.
PART II Other Information
Item 6.



1

PART I. FINANCIAL INFORMATION

ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
September 30,
2022		June 30,
2022
ASSETS
Current assets:
Cash and cash equivalents$275,147 $593,869 
Restricted cash256,176 256,165 
Accounts receivable, net1,650,922 1,541,750 
Inventories, net1,617,000 1,603,955 
Other current assets216,540 190,043 
Total current assets4,015,785 4,185,782 
Property and equipment, net46,177 52,660 
Right-of-use assets717,345 788,257 
License, net
84,903 82,750 
Other long term assets62,788 62,788 
Total assets$4,926,998 $5,172,237 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Line of credit $201,575 $201,575 
Current portion of note payable 3,401 3,401 
Current portion of EIDL loan2,888 3,105 
Accounts payable1,289,847 1,012,451 
Accrued expenses842,045 901,996 
Related party accrued interest 112,389 112,389 
Current portion of operating lease liabilities
310,921 304,737 
Deferred revenue274,118 332,383 
Other short-term liabilities120,861 129,961 
Total current liabilities3,158,045 3,001,998 
Note payable, net of current portion3,201 3,888 
EIDL loan, net of current portion 149,269 149,540 
Operating lease liabilities, net of current portion459,190 538,794 
Total long-term liabilities611,660 692,222 
Total liabilities3,769,705 3,694,220 
Shareholders' equity:
Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized; 2,000,000 shares issued and outstanding (liquidation value of $883,737 and $870,731)645,000 645,000 
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding 7,415 7,415 
Additional paid-in capital69,702,043 69,702,043 
Accumulated deficit(69,197,165)(68,876,441)
Total shareholders’ equity1,157,293 1,478,017 
Total liabilities and shareholders’ equity$4,926,998 $5,172,237 
See notes to unaudited condensed consolidated financial statements
2


ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
For the Three Months Ended September 30,
20222021
Net revenues:
Products$2,442,337 $2,479,777 
Service plans162,479 195,292 
Revenues, net2,604,816 2,675,069 
Costs and expenses:
Cost of goods sold1,548,372 1,663,874 
Marketing, general and administrative1,108,100 904,491 
Research and development264,241 291,189 
Total costs and expenses
2,920,713 2,859,554 
Loss from operations(315,897)(184,485)
Other (expense) income
Other income— 506,305 
Interest expense(4,827)(4,600)
Total other (expense) income, net(4,827)501,705 
Net (loss) income(320,724)317,220 
Undeclared dividends on preferred stocks13,006 13,006 
$(333,730)$304,214 
Net (loss) earning per share
Basic (loss) earnings per share$(0.05)$0.04 
Diluted (loss) earnings per share$(0.05)$0.02 
Weighted average shares—basic7,415,329 7,415,329
Weighted average shares—diluted7,415,32912,876,202
See notes to unaudited condensed consolidated financial statements
3


ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
FOR THE THREE ENDED SEPTEMBER 30, 2022 AND SEPTEMBER 30, 2021
(UNAUDITED)


 Series A Convertible Preferred StockCommon StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Shareholders’
Equity
 Shares AmountSharesAmount  
Balance at June 30, 20222,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,876,441)$1,478,017 
Net loss— — — — — (320,724)(320,724)
Balance at September 30, 20222,000,000 $645,000 7,415,329 $7,415 69,702,043 (69,197,165)1,157,293 

 Series A Convertible Preferred StockCommon StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Shareholders’
Equity
 Shares AmountSharesAmount  
Balance at June 30, 20212,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,894,522)$1,459,936 
Net income— — — — — 317,220 317,220 
Balance at September 30, 20212,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,577,302)$1,777,156 


See notes to unaudited condensed consolidated financial statements
4

ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
For Three Months Ended September 30,
2022
2021
Cash Flows from Operating Activities:
Net (loss) income$(320,724)$317,220 
Adjustments to reconcile net loss to net cash used in operating activities:
Increase in allowance of doubtful accounts5,000 15,000 
Other income
— (506,305)
Depreciation and amortization
11,485 13,450 
Non cash lease expense
105,573 68,718 
Change in operating assets and liabilities:
Accounts receivable(114,172)(291,148)
Inventories(13,045)28,929 
Other current and non-current assets(26,497)(8,551)
Accounts payable 277,396 19,617 
   Accrued expenses
(59,951)109,519 
Change in operating lease liability
(108,081)(70,303)
Deferred revenue(58,265)(87,432)
  Other short term and long term liabilities(9,100)(2,100)
Net cash used in operating activities(310,381)(393,386)
Cash Flows from Investing Activities:
Purchase of licenses
(7,155)— 
Net cash used in investing activities
(7,155)— 
Cash Flows from Financing Activities:
Repayment of note payable(687)(958)
Repayment of EIDL loan(488)(705)
Net cash used in financing activities(1,175)(1,663)
Net decrease in cash, cash equivalents and restricted cash(318,711)(395,049)
Cash, cash equivalents and restricted cash, beginning of period850,034 1,906,890 
Cash, cash equivalents and restricted cash, end of period$531,323 $1,511,841 
Cash, cash equivalents and restricted cash consist of the following:
End of period
Cash and cash equivalents$275,147 $1,255,824 
Restricted cash 256,176 256,017 
$531,323 $1,511,841 
5

Beginning of period
Cash and cash equivalents$593,869 $1,650,970 
Restricted cash 256,165 255,920 
$850,034 $1,906,890 

Supplemental Schedule of Cash Flow Information:
Interest paid$5,273 $4,697 
Non Cash Finance Activities
See notes to unaudited condensed consolidated financial statements
6

Escalon Medical Corp. and Subsidiaries
Notes to Unaudited Condensed Consolidated Financial Statements

1. Organization and Basis of Presentation

          Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc.

    The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.

    The unaudited condensed consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, and reflect all adjustments (consisting of only normal and recurring adjustments) which are, in the opinion of management, necessary to present fairly the unaudited condensed consolidated financial information required herein. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United Statements of America ("US GAAP") have been condensed or omitted pursuant to such rules and regulations. While management believes that the disclosures are adequate to make the information presented not misleading, it is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed with the Security and Exchange Commission for the fiscal year ended June 30, 2022. The results of operations for the three months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full year.

In February 2022, Russia invaded Ukraine. As military activity proceeds and sanctions, export controls and other measures are imposed by many countries against Russia, Belarus and specific areas of Ukraine, the war is increasingly affecting the global economy and financial markets, as well as exacerbating ongoing economic challenges, including rising inflation and global supply-chain disruption. The Company has operations or activities in countries and regions outside the United States. As a result, its global operations are affected by economic, political and other conditions in the foreign countries in which the Company has business as well as U.S. laws regulating international trade, although the Company has not yet assessed that the war has had a material effect on its financial position or results of operations. The Company will continue to monitor the impacts of the Russia-Ukraine war on macroeconomic conditions and continually assess the effect these matters may have on customer demand, suppliers’ ability to deliver products, cybersecurity risks and its liquidity and access to capital.

    The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”

2. Going Concern

The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the continuous enhancement of the current products, development of new products; changes in domestic and foreign regulations; ability of manufacture successfully; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products and its ability to raise capital to support its operations.

To date, the Company’s operations have not generated sufficient revenues to enable profitability. As of September 30, 2022, the Company had an accumulated deficit of $69.2 million, and incurred recurring losses from operations and incurred negative cash flows from operating activities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for the next 12 months following the issuance of these unaudited condensed consolidated financial statements.

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
7


The Company's continuance as a going concern is dependent on its future profitability and on the on-going support of its shareholders, affiliates and creditors. In order to mitigate the going concern issues, the Company is actively pursuing business partnerships, managing its continuing operations, implementing cost-cutting measures and seeking to sell certain assets. The Company may not be successful in any of these efforts.

3. Summary of Accounting Policies

Quarterly Reporting
The accompanying unaudited condensed consolidated financial statements (“financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and have been consistently applied. Certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP, but which are not required for interim reporting purposes, have been omitted. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to present fairly the financial position as of September 30, 2022 and the results of operations and cash flows for the interim periods ended September 30, 2022 and 2021, have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended June 30, 2022 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on September 28, 2022. Operating results for the three months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the full year ending June 30, 2023.
Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable

Accounts receivable are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company recorded an allowance for doubtful accounts of approximately $241,000 and $236,000 as of September 30, 2022 and June 30, 2022, respectively.

Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the Company’s forecasts of future sales and age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely impact the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year.

PPP Loans
8

    The Company's policy is to account for the PPP loan (See Note 7) as debt. The Company will continue to record the loan as debt until either (1) the loan is partially or entirely forgiven and the Company has been legally released, at which point the amount forgiven will be recorded as income or (2) the Company pays off the loan. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021 and was included in other income in the unaudited condensed consolidated income statement for the three-month period ended September 30, 2021.

Deferred Revenues

    The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plans for a 12-month period. The consideration received is recognized monthly over the service period.

(in thousands)Three Months Ended September 30,
20222021
Beginning of Period$332 $364 
Additions104107
Revenue Recognized162 195 
End of Period$274 $276 

(Loss) earnings Per Share    
(Loss) earnings per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of September 30, 2022, and 2021, the average market prices for the three-month periods then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three-month periods ended September 30, 2022. Therefore, basic and diluted loss per common share for the three-month periods ended September 30, 2022 are the same.
9

For the Three Months Ended September 30,
20222021
Numerator:
  Numerator for basic loss per share:
 Net (loss) income$(320,724)$317,220 
Undeclared dividends on preferred stock$13,006 13,006 
Net (loss) income applicable to common shareholders$(333,730)$304,214 
Numerator for diluted earnings per share:
Net (loss) income applicable to common shareholders$(333,730)$304,214 
Undeclared dividends on preferred stock13,006 13,006 
Diluted (loss) income$(320,724)$317,220 
Denominator for basic (loss) earnings per share
Denominator for basic (loss) earnings per share - weighted average shares outstanding
7,415,3297,415,329 
Weighted average preferred stock converted to common stock— 5,460,873 
 Denominator for diluted (loss) earnings assumed conversion7,415,329 12,876,202 
Net (loss) earnings per share:
Basic net (loss) earnings per share$(0.05)$0.04 
Diluted net (loss) earnings per share$(0.05)$0.02 

The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.

10

11

For the Three Months Ended September 30,
20222021
Stock options157,000 157,000 
Convertible preferred stock5,891,580 — 
Total potential dilutive securities not included in income per share6,048,580 157,000 

Income Taxes

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of September 30, 2022 and June 30, 2022, the Company has a fully recorded valuation allowance against its deferred tax assets.

    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of September 30, 2022 and June 30, 2022, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited condensed consolidated balance sheets.

4. Inventories

September 30,
June 30,
(in thousands)20222022
Inventories:
        Raw Material$1,028 $1,010 
        Work-In-Process154 138 
        Finished Goods785 806 
Total inventories$1,967 $1,954 
Allowance for obsolete inventory(350)(350)
Inventories, net$1,617 $1,604 

5. Related Party Transactions and Preferred Stock

    On February 14, 2018, the Company entered into a Debt Exchange Agreement (the “Exchange Agreement”) with Richard DePiano, Sr., (Mr. DePiano Sr.), the Company's former Chairman and DP Associates Inc. Profit-Sharing Plan of
12

which Mr. DePiano Sr. is the sole owner and sole trustee (the “Holders”).  Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program the Company owes the Holders for 2,000,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”).
    
    Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders.  As a result of this voting power, the Holders as September 30, 2022 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company’s shareholders.

    Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the “Conversion Ratio”).  The Conversion Ratio is subject to standard provisions for adjustment in the event of a subdivision or combination of the Company’s Common Stock and upon any reorganization or reclassification of the capital stock of the Company. If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the then outstanding shares of Common Stock assuming such conversion.

    Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock. Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full. The dividends payable to the holders of the Preferred Stock is payable in cash or, at the election of any such holder, in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then applicable Conversion Ratio, described above. As of September 30, 2022 and June 30, 2022 the cumulative dividends payable is $238,737 ($0.1194 per share) and $225,731 ($0.1129 per share), respectively.

    Mr. DePiano Sr. passed away on October 3, 2019 and left a will by which he appointed Richard J. DePiano, Jr., the Chief Executive Officer of the Company, as executor. Richard DePiano Jr. was elected to serve as chairman of the Company's board. Mr. DePiano, Jr. qualified as executor and has control over the listed shares in his capacity as executor of Mr. DePiano Sr.'s estate.

6. Line of Credit

    On June 29, 2018 the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.0% per annum. Interest on the unpaid principal balance of the note is calculated using a rate of 0.74 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.74% per annum based on a year of 360 days. The interest rate was 6.54% as of September 30, 2022. The Company was required to put $250,000 in the TD bank savings account as collateral. The Loan is now guaranteed by Mr. DePiano Jr.

    As of September 30, 2022 and June 30, 2022, the line of credit balance was $201,575 with TD bank. The line of credit interest expense was approximately $3,000 for the three months ended September 30, 2022 and 2021, respectively.

7. Long-term debt

Paycheck Protection Program ("PPP") loan

    On April 27, 2020, the Company entered into a PPP loan for $500,000 in connection with the CARES Act related to COVID-19. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021 and was included in other income in the unaudited condensed consolidated statement of operations for the three-month period ended September 30, 2021.

Economic Injury Disaster ("EIDL") Loan

    EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal
13

operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received a $150,000 EIDL loan. The annual interest rate is 3.75%. The payment term is 30 years and the monthly payment of $731 started on July 1st, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company.

    The future annual principal amounts to be paid as of September 30, 2022 are as follows:
Year ending June 30,EIDL Payment
2023 (remainder of FY 2023)2,631 
20243,237 
20253,376 
20263,497 
Thereafter139,416 
Total$152,157 

Other short-term Liabilities

    The CARES Act allows employers to defer the deposit and payment of the employer share of Social Security tax that would otherwise be due on or after March 27, 2020, and before January 1, 2021. The Company had deferred approximately $82,000 of the social security tax. 50% of the deferred employment taxes was paid before December 31, 2021. The remaining 50% is not due until December 31, 2022. Approximately $41,000 was reported as short-term other liabilities as of September 30, 2022.

8. Concentration of Credit Risk

Credit Risk

Financial instruments, which potentially subject the Company to concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely address the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral.

Major Customer

    No customer accounted for more than 10% of net sales during the three-month period ended September 30, 2022. One customer accounted for 13% during the three-month period ended September 30, 2021.

    As of September 30, 2022 the Company had one customer that represented 11% of the total accounts receivable balance. As of June 30, 2022 the Company had one customer that represents 13% of the total accounts receivable balance.

Major Supplier

    The Company's one largest supplier accounted for 38% of the total purchase for the three-month period ended September 30, 2022. The Company's three largest suppliers accounted for 32%, 13% and 11% of total purchases for the three-month period ended September 30, 2021.

    As of September 30, 2022 the Company had two supplier that represented 33% and 13% of the total accounts payable balance. As of June 30, 2022 the Company had one suppliers that represent approximately 36% of the total accounts payable balance.
14

Disaggregated Revenue

    Domestic and international sales from operations are as follows:
( in thousands)For the Three Months Ended September 30,
20222021
Domestic$1,620 62.2 %$1,625 60.7 %
Foreign985 37.8 %$1,050 39.3 %
Total$2,605 100 %$2,675 100 %

9. Leases

    The Company leases certain facilities and equipment under operating leases. Total lease expense, under ASC 842, was included in cost of goods sold and marketing, general and administrative costs in our unaudited condensed consolidated statements of operations for the three months ended September 30, 2022 and 2021 as follows:

Three Months Ended September 30,
20222021
Operating lease costs:
Fixed$85,436 $84,245 
Total:$85,436 $84,245 

    Supplemental cash flow information was as follows:
Three Months Ended September 30,
20222021
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases$84,592 $82,390 
Total$84,592 $82,390 


    The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate)
under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheets as of September 30, 2022:
Operating
2023 (reminder of FY 2023)258,649 
2024350,142 
2025211,215 
20262,728 
Total lease payments822,734 
Less interest 52,622 
Present value of lease liabilities$770,112 

    Average lease terms and discount rates were as follows:
15

September 30, June 30,
20222022
Weighted-average remaining lease terms (years)
Operating leases
2.362.61
Weighted-average discount rate
Operating leases
5.65 %5.65 %

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

    Certain statements contained in, or incorporated by reference in, this report are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which provide current expectations or forecasts of future events. Such statements can be identified by the use of terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “possible,” “project,” “should,” “will,” and similar words or expressions. The Company's forward-looking statements include certain information relating to general business strategy, growth strategies, financial results, liquidity, the Company's ability to continue as a going concern, discontinued operations, research and development, product development, the introduction of new products, the potential markets and uses for the Company's products, the Company's ability to increase its sales campaign effectively, the Company's regulatory filings with the FDA, acquisitions, dispositions, the development of joint venture opportunities, intellectual property and patent protection and infringement, the loss of revenue due to the expiration or termination of certain agreements, the effect of competition on the structure of the markets in which the Company competes, increased legal, accounting and Sarbanes-Oxley compliance costs, information security, cybersecurity and data privacy risks, defending the Company in litigation matters and the Company's cost saving initiatives. The reader must carefully consider forward-looking statements and understand that such statements involve a variety of risks and uncertainties, known and unknown, and may be affected by assumptions that fail to materialize as anticipated, including risks related to the COVID-19 pandemic, inflation, the ability to continue as a going concern including the abilityto raise capital, manage operations and pursue business partnerships and cost-cutting measures, and the other risks described in the Company's Form 10-K for the fiscal year ended June 30, 2022. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. It is not possible to foresee or identify all factors affecting the Company's forward-looking statements, and the reader therefore should not consider the list of such factors contained in its periodic report on Form 10-K for the year ended June 30, 2022 and this Form 10-Q quarterly report to be an exhaustive statement of all risks, uncertainties or potentially inaccurate assumptions.

Executive Overview—three-month periods ended September 30, 2022 and 2021
The following highlights are discussed in further detail within this Form 10-Q. The reader is encouraged to read this Form 10-Q in its entirety to gain a more complete understanding of factors impacting Company performance and financial condition.

•Consolidated net revenue decreased approximately $70,000 or 2.6%, to $2,605,000 during the three months ended September 30, 2022, as compared to the same period of last fiscal year. The decrease in net revenue is attributed to a decrease in sales in Trek revenue of $143,000, and a decrease in service plans revenue of $33,000 offset by an increase in Sonomed's ultrasound products of $94,000, and an increase in sales of AXIS products of $12,000.

•Consolidated cost of goods sold totaled approximately $1,548,000, or 59.4%, of total revenue for the three months ended September 30, 2022, as compared to $1,664,000, or 62.2%, of total revenue of the same period of last fiscal year. The decrease of 2.8% in cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and geographic differences.

•Consolidated marketing, general and administrative expenses increased $204,000, or 22.6%, to $1,108,000 for the three months ended September 30, 2022, as compared to the same period of last fiscal year. The increase in marketing, general and administrate expenses is mainly due to increased expense for network improvement, increased consulting expense related to a regulatory filing related to AXIS products, increased trade show and travel expense and the increased sales compensation.
16


•Consolidated research and development expenses decreased $27,000, or 9.3%, to $264,000 for the three months ended September 30, 2022, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expense is mainly due to increased consulting expense during the three months ended September 30, 2022.
Company Overview

    The following discussion should be read in conjunction with the interim unaudited condensed consolidated financial statements and the notes thereto, which are set forth in Item 1 of this report.

    The Company operates in the healthcare market specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the FDA. The FDA requires extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing. The Company's Internet address is www.escalonmed.com. Under the trade name of Sonomed-Escalon the Company develops, manufactures and markets ultrasound systems used for diagnosis or biometric applications in ophthalmology, develops, manufactures and distributes ophthalmic surgical products under the Trek Medical Products name, and manufactures and markets image management systems.
Critical Accounting Policies and Estimates
The preparation of unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact amounts reported therein. On a regular basis, we evaluate these estimates. These estimates are based on management’s historical industry experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

For a description of the accounting policies that, in management’s opinion, involve the most significant application of judgment or involve complex estimation and which could, if different judgment or estimates were made, materially affect our reported financial position, results of operations, or cash flows, see the notes to consolidated financial statements included in the Form 10-K for the year ended June 30, 2022.

During the three months ended September 30, 2022, there were no significant changes in our accounting policies and estimates to our unaudited condensed consolidated financial statements.
17

Results of Operations
Three Months Ended September 30, 2022, and 2021
The following table shows consolidated net revenue, as well as identifying trends in revenues for the three months ended September 30, 2022, and 2021. Table amounts are in thousands:
 For the Three Months Ended September 30,
 20222021% Change
Net Revenue:
Products$2,443 $2,480 (1.5)%
Service plans162 195 (16.9)%
Total$2,605 $2,675 (2.6)%
    
Consolidated net revenue decreased approximately $70,000 or 2.6%, to $2,605,000 during the three months ended September 30, 2022, as compared to the same period of last fiscal year. The decrease in net revenue is attributed to a decrease in sales in Trek revenue of $143,000, and a decrease in service plans revenue of $33,000 offset by an increase in Sonomed's ultrasound products of $94,000, and an increase in sales of AXIS products of $12,000.

The following table presents the domestic and foreign sales for the three months ended September 30, 2022, and 2021. The table amounts are in thousands:
For the Three Months Ended September 30,
20222021
Domestic$1,620 62.2 %$1,625 60.7 %
Foreign985 37.8 %1,050 39.3 %
Total$2,605 100.0 %$2,675 100.0 %

The following table presents consolidated cost of goods sold and as a percentage of revenues for the three months ended September 30, 2022, and 2021. Table amounts are in thousands:
 
 For the Three Months Ended September 30,
 2022%2021%
Cost of Goods Sold:
$1,548 59.4 %$1,664 62.2 %
Total$1,548 59.4 %$1,664 62.2 %

Consolidated cost of goods sold totaled approximately $1,548,000, or 59.4%, of total revenue for the three months ended September 30, 2022, as compared to $1,664,000, or 62.2%, of total revenue of the same period of last fiscal year. The decrease of 2.8% in cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and geographic differences.


    The following table presents consolidated marketing, general and administrative expenses for three months ended September 30, 2022 and 2021. Table amounts are in thousands:
 
 For the Three Months Ended September 30,
 20222021% Change 
Marketing, General and Administrative:
$1,108 $904 22.6 %
Total$1,108 $904 22.6 %

18

Consolidated marketing, general and administrative expenses increased $204,000, or 22.6%, to $1,108,000 for the three months ended September 30, 2022, as compared to the same period of last fiscal year. The increase in marketing, general and administrate expenses is mainly due to increased expense for network improvement, increased consulting expense related to a regulatory filing relatedto AXIS products, increased trade show and travel expense and the increased sales compensation.
The following table presents consolidated research and development expenses for the three months ended September 30, 2022 and 2021.
Table amounts are in thousands:
For Three Months Ended September 30,
 20222021% Change
Research and Development:
264 $291 (9.3)%
Total$264 $291 (9.3)%

Consolidated research and development expenses decreased $27,000, or 9.3%, to $264,000 for the three months ended September 30, 2022, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expense is mainly due to decreased consulting expense during the three months ended September 30, 2022.

Other income
  
On April 27, 2020, the Company entered into a PPP loan for $500,000 in connection with the CARES Act related to COVID-19. The promissory note has a fixed payment schedule. The PPP loan is unsecured. A final payment for the unpaid principal and accrued interest will be payable no later than two years after the funding date. The note will bear interest at a rate of 1.00% per annum. The Company submitted the loan forgiveness application on August 2, 2021. The full amount of the PPP loan and accrued interest of $6,305 were forgiven on August 13, 2021 and reported as other income during the three-month period ended September 30, 2021.


Russia-Ukraine War

In February 2022, Russia invaded Ukraine. As military activity proceeds and sanctions, export controls and other measures are imposed by many countries against Russia, Belarus and specific areas of Ukraine, the war is increasingly affecting the global economy and financial markets, as well as exacerbating ongoing economic challenges, including rising inflation and global supply-chain disruption. The Company has operations or activities in countries and regions outside the United States. As a result, its global operations are affected by economic, political and other conditions in the foreign countries in which it does business as well as U.S. laws regulating international trade, although the Company has not yet assessed that the war has had a material effect on its financial position or results of operations.

Liquidity and Capital Resources

Our total cash on hand as of September 30, 2022 was approximately $275,000 of cash on hand and restricted cash of approximately $256,000 compared to approximately $594,000 of cash on hand and restricted cash of $256,000 as of June 30, 2022. Approximately $48,000 was available under our line of credit as of September 30, 2022.

Because the Company's operations have not historically generated sufficient revenues to enable profitability, we will continue to monitor costs and expenses closely and may need to raise additional capital or take other actions in order to fund operations.

The Company expects to continue to fund operations from cash on hand and through capital raising sources if possible and available, which may be dilutive to existing stockholders, through revenues from the licensing of the Company's products, or through strategic alliances. Additionally, we may seek to sell additional equity or debt securities
19

through one or more discrete transactions, or enter into a strategic alliance arrangement, but can provide no assurances that any such financing or strategic alliance arrangement will be available on acceptable terms, or at all. Moreover, the incurrence of indebtedness in connection with a debt financing would result in increased fixed obligations and could contain covenants that would restrict our operations.

As of September 30, 2022 we had an accumulated deficit of approximately $69.2 million, incurred recurring losses from operations and negative cash flows from operating activities. These factors raise substantial doubt regarding our ability to continue as a going concern, and our ability to generate cash to meet our cash requirements for the following twelve months as of the date of this form 10-Q.
    
The following table presents overall liquidity and capital resources as of September 30, 2022 and June 30, 2022. Table amounts are in thousands:
 
September 30,June 30,
 20222022
Current Ratio:
Current assets$4,016$4,186
Less: Current liabilities3,1583,002
Working capital$858$1,184
Current ratio1.27 to 11.39 to 1
Debt to Total Capital Ratio:
Line of credit, note payable, lease liabilities, and EIDL loan$1,130$1,205
Total debt 1,1301,205
Total equity 1,1571,478
Total capital $2,287$2,683
Total debt to total capital 49.4%44.9%
20

Working Capital Position
Working capital decreased approximately $326,000 as of September 30, 2022, and the current ratio decreased to 1.27 to 1 from 1.39 to 1 when compared to June 30, 2022. The decrease in working capital is due to an increase in current liabilities of $156,000 during the quarter ended September 30, 2022, and a decrease in current assets of $170,000.
Debt to total capital ratio was 49.4% and 44.9% as of September 30, 2022 and June 30, 2022, respectively. The increase of debt to total capital ratio is due to operating loss.
Cash Flow Used in Operating Activities
During the three months ended September 30, 2022 the Company used approximately $310,000 of cash in operating activities as compared to cash of approximately $393,000 provided by operating activities during the three months ended September 30, 2021.
    For the three months ended September 30, 2022, its cash used in operations is mainly as a result of net loss, along with an increase in inventories of $13,000, an increase in other assets of $26,000, an increase in accounts receivable of approximately $114,000, a decrease in deferred revenue of $58,000, and a decrease in accrued expense of $60,000 offset by an increase in accounts payable of $277,000. The remaining offsetting items for cash provided by operations is comprised of less significant items.
    For the three months ended September 30, 2021, its cash used in operations is mainly due to increase in accounts receivable of approximately 291,000, a decrease in deferred revenue of $87,000 and decrease in operating liabilities of $70,000 offset by an increase in accrued expense of $110,000. The remaining offsetting items for cash provided by operations is comprised of less significant items.
Cash Flows used in Investing Activities
Cash flows used in investing activities for the three-month period ended September 30, 2022 was due to the addition to the patent of $7,000. There were no cash flows used in investing activities for the three-month period ended September 30, 2021.
Cash Flows Used in Financing Activities
For the three months ended September 30, 2022 the cash used in financing activities was due to an auto loan payment of $700 and repayment of EIDL loan of $500. For the three months ended September 30, 2021 the cash used in financing activities was due to auto loan payment of $1,000 and repayment of EIDL loan accrued interest of $700.
Debt Financing

    On June 29, 2018 the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.000% per annum. Interest on the unpaid principal balance of the note will be calculated using a rate of 0.740 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.740% per annum based on a year of 360 days. The interest rate was 6.54% as of September 30, 2022. The Company was required to put $250,000 in the TD bank savings account as collateral.
    
    As of September 30, 2022 and June 30, 2022, the line of credit balance was $201,575 with TD bank. The line of credit interest expense was approximately $3,000 and $3,000 for the three months ended September 30, 2022 and 2021, respectively.

COVID-19 Relief Loans and Liabilities

Payroll Protection Program ("PPP")

    On April 27, 2020, the Company entered into a PPP loan for $500,000 in connection with the CARES Act related to COVID-19. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021 and reported as other income during the three-month period ended September 30, 2021.

Economic Injury Disaster Loan ("EIDL")

    EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received
21

$150,000 EIDL loan. The annual interest rate is 3.75%, the payment term is 30 years and the monthly payment of $731 started on July 1st, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company.

Employer Payroll Tax Withholding

    The CARES Act allows employers to defer the deposit and payment of the employer share of Social Security tax that would otherwise be due on or after March 27, 2020, and before January 1, 2021. The Company has deferred approximately $82,000 of the social security tax. 50% of the deferred employment taxes was paid before December 31, 2021. The remaining 50% is not due until December 31, 2022. Approximately $41,000 was reported as short-term other liabilities as of September 30, 2022.


Item 3.    Quantitative and Qualitative Disclosures About Market Risk

None

Item 4. Controls and Procedures

(A)    Evaluation of Disclosure Controls and Procedures

The Company's management, with the participation of the Company's Chief Executive Officer and Principal Financial and Accounting Officer, have established disclosure controls and procedures to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the officers who certify the Company's financial reports and to other members of senior management and the Board of Directors.

Based on their evaluation of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2022, the Chief Executive Officer and Principal Financial and Accounting Officer of the Company have concluded that such disclosure controls and procedures are not effective to ensure that the information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its Chief Executive Officer and Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosure. We identified a material weakness in internal control related to the proper design and implementation of controls over our estimates relating to the valuation of inventory and allowance for doubtful accounts, specifically over the precision of management’s review during the year end June 30, 2022.


(B)    Internal Control over Financial Reporting

There have not been any changes in the Company's internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act), during the first quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Part II. OTHER INFORMATION

Item 6.    Exhibits


Signatures
22
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Escalon Medical Corp.
(Registrant)
Date: November 14, 2022By:/s/ Richard J. DePiano, Jr.
Richard J. DePiano, Jr.
Chief Executive Officer
Date: November 14, 2022By:/s/ Mark Wallace
Mark Wallace
Chief Operating Officer and Principal Accounting & Financial Officer

 EX-31.1 2 esmc_2022930-10qex311.htm EX-31.1 Document

Exhibit 31.1
Certification of Principal Executive Officer
I, Richard J. DePiano, certify that:
1.I have reviewed this annual report on Form 10-Q of Escalon Medical Corp.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/    Richard J. DePiano Jr.
Richard J. DePiano Jr.
Chief Executive Officer
Date: November 14, 2022


 EX-31.2 3 esmc_2022930-10qex312.htm EX-31.2 Document

Exhibit 31.2


Certification of Principal Financial Officer
I, Mark Wallace, certify that:
1.I have reviewed this annual report on Form 10-Q of Escalon Medical Corp.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/    Mark Wallace
Mark Wallace
Date: November 14, 2022


 EX-32.1 4 esmc_2022930-10qex321.htm EX-32.1 Document

Exhibit 32.1

Certification pursuant to 18 U.S.C. Section 1350,
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, Richard J. DePiano Jr., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Quarterly Report of Escalon Medical Corp. on Form 10Q for the quarterly period ended September 30, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2022
 
/s/    Richard J. DePiano Jr.
Richard J. DePiano Jr.
Chief Executive Officer



 EX-32.2 5 esmc_2022930-10qex322.htm EX-32.2 Document

Exhibit 32.2

Certification pursuant to 18 U.S.C. Section 1350,
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Mark Wallace, Chief Operating Officer and Principal Accounting & Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Quarterly Report of Escalon Medical Corp. on Form 10-Q for the quarterly period ended September 30, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: , 2022
 
/s/    Mark Wallace
Mark Wallace
Chief Operating Officer and Principal Accounting & Financial Officer



 EX-101.SCH 6 esmc-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Statements Of Operations link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements Of Shareholders' Equity and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Going concern (Notes) link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Inventory (Notes) link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Long term debt (Notes) link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Line of credit (Notes) link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Concentration of credit risk (Notes) link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Leases (Notes) link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Going concern (Tables) link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Long term debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Concentration of credit risk (Tables) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Going concern (Details) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Significant Accounting Policies (Cash and Cash Equivalents) (Details) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Significant Accounting Policies (Inventory) (Details) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Significant Accounting Policies (Accounts Receivable) (Details) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Significant Accounting Policies (Net Income (loss) Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Significant Accounting Policies Earning per share details (Details) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Significant Accounting Policies Goodwill and intangible assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Significant Accounting Policies Income tax (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Significant Accounting Policies deferred revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Significant Accounting Policies New accounting pronouncements recently adopted (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Long term debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Line of credit (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Concentration of credit risk (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 esmc-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 esmc-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 esmc-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Geographic Concentration Risk [Member] Geographic Concentration Risk [Member] Other Short-term Borrowings Other Short-Term Borrowings Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Operating Leases, Future Minimum Payments Due Lessee, Operating Lease, Liability, to be Paid Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Transactions and Translations Policy [Policy Text Block] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Accounts Receivable, Credit Loss Expense (Reversal) Accounts Receivable, Credit Loss Expense (Reversal) Geographical [Domain] Geographical [Domain] Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Finance Lease, Liability, to be Paid, Year Four Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Cost of Goods and Services Sold Cost of Goods and Services Sold Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted Weighted average shares - diluted Weighted Average Number of Shares Outstanding, Diluted Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Two Concentration Risk Disclosure [Text Block] Concentration Risk Disclosure [Text Block] Schedule of Inventory, Current [Table Text Block] Schedule of Inventory, Current [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] PPP loan amount PPP loan amount PPP loan amount Accounts Receivable Accounts Receivable [Member] Supplier one [Member] Supplier one [Member] Supplier one [Member] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Other (expense) income: Other Income and Expenses [Abstract] Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Preferred Stock [Member] Preferred Stock [Member] Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Basis Spread on Variable Rate Notes Payable to Bank Notes Payable to Bank Statistical Measurement [Domain] Statistical Measurement [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Preferred stock, shares authorized Preferred Stock, Shares Authorized Supplier three [Member] Supplier three [Member] Supplier three [Member] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning of Period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, End of Period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Other Noncash Income (Expense) us-gaap_OtherNonoperatingIncomeExpensenoncash Other Noncash Income (Expense) Current liabilities: Liabilities, Current [Abstract] Net Income (Loss) Available to Common Stockholders, Basic Net Income (Loss) Available to Common Stockholders, Basic Net Income (Loss) Available to Common Stockholders, Basic Going concern [Abstract] Going concern [Abstract] Going concern [Abstract] Common stock, shares issued Common Stock, Shares, Issued Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic Concentration Risk [Line Items] Concentration Risk [Line Items] Net (loss) income Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Deposits Assets, Noncurrent Deposits Assets, Noncurrent Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of Maturities of Long-Term Debt [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Total Shareholders' Equity [Domain] Equity Component [Domain] Amendment Flag Amendment Flag Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Investing Activities Operating Lease, Cost Operating Lease, Cost Subsequent Event Type [Domain] Subsequent Event Type [Domain] Secured Debt [Member] Secured Debt [Member] Equity Method Investee, Name [Domain] Investment, Name [Domain] Earning per share [Abstract] Earning per share [Abstract] Earning per share [Abstract] Lease Lessee, Operating Leases [Text Block] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Entity Current Reporting Status Entity Current Reporting Status Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Preferred Stock Dividends, Income Statement Impact Preferred Stock Dividends, Income Statement Impact Other short-term liabilities Other Liabilities, Current Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Supplemental Schedule of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Customer Two [Member] Customer Two [Member] Customer Two [Member] Repayments of Notes Payable Repayments of Notes Payable Total long-term liabilities Liabilities, Noncurrent Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Dividends Payable, Amount Per Share Dividends Payable, Amount Per Share Entity Address, State or Province Entity Address, State or Province Lease term Lessee, Operating Lease, Term of Contract Counterparty Name [Axis] Counterparty Name [Axis] Concentration Risk, Supplier Concentration Risk, Supplier Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion DisposeLeaseLiabilities DisposeLeaseLiabilities DisposeLeaseLiabilities Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Operating Activities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Operating Lease, Liability, Current Operating Lease, Liability, Current Property and equipment, net Property, Plant and Equipment, Net EIDL Monthly Payment including Principal and Interest EIDL Monthly Payment including Principal and Interest MonthlyFixedPayment Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Costs and expenses: Costs and Expenses [Abstract] Lender Name [Axis] Lender Name [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Interest portion in the future lease payments Interest portion in the future lease payments Interest portion in the future lease payments Long-term Debt Long-Term Debt Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) Common stock, shares authorized Common Stock, Shares Authorized Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Revenue Recognition and Deferred Revenue [Abstract] Revenue Recognition and Deferred Revenue [Abstract] Total liabilities Liabilities Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Geographical [Axis] Geographical [Axis] Cash Flows from Investing Activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Inventory, Work in Process, Gross Inventory, Work in Process, Gross Concentration Risk, Customer Concentration Risk, Customer Total current assets Assets, Current Preferred Stock, Shares Issued Preferred Stock, Shares Issued Document Type Document Type Entity Small Business Entity Small Business Long-term Debt [Text Block] Long-Term Debt [Text Block] Payroll Protection Program Loan [Member] Payroll Protection Program Loan [Member] Payroll Protection Program Loan [Member] Shares, Outstanding Shares, Outstanding Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Wisconsin Warehouse Wisconsin Warehouse [Member] Wisconsin Warehouse Finite-Lived Intangible Assets, Net Finite-Lived Intangible Assets, Net Line of Credit Facility [Table] Line of Credit Facility [Table] Restricted Cash Restricted Cash Debt Disclosure [Text Block] Debt Disclosure [Text Block] Significant Accounting Policies Significant Accounting Policies [Text Block] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Contractual Obligation, Fiscal Year Maturity Contractual Obligation, Fiscal Year Maturity [Table Text Block] Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Deferred Revenue Increase (Decrease) in Deferred Revenue Concentration Risk [Table] Concentration Risk [Table] Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year Lessee, Operating Lease, Liability, to be Paid, Year One Other Long-term Debt Other Long-Term Debt Increaser(Decrease) in Accounts Receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Long-Term Debt, Maturity, Year Three Long-Term Debt, Maturity, Year Three New accounting pronouncements recently adopted [Abstract] New accounting pronouncements recently adopted [Abstract] New accounting pronouncements recently adopted [Abstract] Subsequent Event Subsequent Event [Member] Revenue Benchmark [Member] Revenue Benchmark [Member] Document Period End Date Document Period End Date Increase (Decrease) in Other Deferred Liability Increase (Decrease) in Other Deferred Liability Costs and Expenses Total costs and expenses Costs and Expenses Debt Instrument [Line Items] Debt Instrument [Line Items] Secured Debt, Current Secured Debt, Current Operating Lease, Liability Operating Lease, Liability Convertible Preferred Stock [Member] Convertible Preferred Stock [Member] Total assets Assets Debt Disclosure [Abstract] Debt Disclosure [Abstract] Supplier [Domain] Supplier [Domain] Net income (loss) per share Earnings Per Share [Abstract] Debt Security Category [Axis] Debt Security Category [Axis] Accounts Receivable Accounts Receivable [Policy Text Block] Maximum maturity of highly liquid investments, period Maximum Maturity of Highly Liquid Investments, Period Maximum maturity of highly liquid investments, period. Supplier [Axis] Supplier [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] Accrued expenses Accrued Liabilities, Current Payments to Acquire Intangible Assets Payments to Acquire Intangible Assets Long-term Debt, Current Maturities Long-Term Debt, Current Maturities Finance Lease, Liability, to be Paid, Year Five Lessee, Operating Lease, Liability, to be Paid, Year Five Net Cash Provided by (Used in) Financing Activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Inventory, net Inventory, Net Accounts payable Accounts Payable, Current Shareholders equity: Stockholders' Equity Attributable to Parent [Abstract] Increase (Decrease) in Other Operating Assets Increase (Decrease) in Other Operating Assets Customer [Axis] Customer [Axis] Record lease liabilities Record lease liabilities Long-Term Debt, Maturity, Year Four Long-Term Debt, Maturity, Year Four Organization and Description of Business and Business Conditions Nature of Operations [Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Entity Filer Category Entity Filer Category Related Party Transaction [Line Items] Related Party Transaction [Line Items] Weighted average shares - basic Basic Weighted average shares outstanding Weighted Average Number of Shares Outstanding, Basic Domestic [Member] UNITED STATES Equity Method Investment, Ownership Percentage Equity Method Investment, Ownership Percentage Inventory, Finished Goods, Gross Inventory, Finished Goods, Gross Entity Registrant Name Entity Registrant Name Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized;2,000,000 issued and outstanding Preferred Stock, Value, Issued Preferred Stock, Value, Issued Supplier Concentration Risk [Member] Supplier Concentration Risk [Member] Restricted Cash, Current Restricted Cash, Current Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Cover [Abstract] Lessee, Leases [Policy Text Block] Lessee, Leases [Policy Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Principles of Consolidation Consolidation, Policy [Policy Text Block] Other Notes Payable, Noncurrent Other Notes Payable, Noncurrent Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value Common Stock, Par or Stated Value Per Share Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Equity Method Investee, Name [Axis] Investment, Name [Axis] Loan Commitments, Policy Loan Commitments, Policy [Policy Text Block] Liquidity Disclosure [Policy Text Block] Substantial Doubt about Going Concern [Text Block] Total liabilities and shareholders' equity Liabilities and Equity Entity File Number Entity File Number Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Research and development Research and Development Expense Interest Payable, Current Interest Payable, Current Accrued Warranties Standard Product Warranty, Policy [Policy Text Block] International [Member] Non-US [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] DisposeROUassets DisposeROUassets DisposeROUassets Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate Current Fiscal Year End Date Current Fiscal Year End Date Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Lessee Disclosure [Abstract] Net Income (Loss) Available to Common Stockholders, Diluted Net Income (Loss) Available to Common Stockholders, Diluted Earnings (Loss) Per Share, Diluted Earnings (Loss) Per Share, Diluted Earnings Per Share, Diluted Use of Estimates Use of Estimates, Policy [Policy Text Block] Common Stock, Voting Rights Common Stock, Voting Rights Inventory, Raw Materials, Gross Inventory, Raw Materials, Gross Equity Option [Member] Equity Option [Member] Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable Concentration Risk, Percentage Concentration Risk, Percentage Revenues Revenues Revenues Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Finance Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Two Other current assets Other Assets, Current Customer Concentration Risk [Member] Customer Concentration Risk [Member] Secured Long-term Debt, Noncurrent Secured Long-Term Debt, Noncurrent Debt Instrument, Periodic Payment Debt Instrument, Periodic Payment Credit Facility [Domain] Credit Facility [Domain] Interest Paid, Excluding Capitalized Interest, Operating Activities Interest Paid, Excluding Capitalized Interest, Operating Activities RecordROUassets RecordROUassets RecordROUassets Earnings (Loss) Per Share, Basic Earnings Per Share, Basic Concentration of credit risks [Abstract] Concentration of credit risks [Abstract] Concentration of credit risks [Abstract] Finance Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid, Year Three Related Party Transaction, Due from (to) Related Party Related Party Transaction, Due from (to) Related Party Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Inventory Inventory, Policy [Policy Text Block] Restrictions on Cash and Cash Equivalents [Table Text Block] Restrictions on Cash and Cash Equivalents [Table Text Block] Convertible Preferred Dividends, Net of Tax Convertible Preferred Dividends, Net of Tax Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Total shareholders' equity Balance Balance Stockholders' Equity Attributable to Parent Product and Service [Axis] Product and Service [Axis] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Interest Expense Interest expense Interest Expense Entity Interactive Data Current Entity Interactive Data Current Supplier two [Member] Supplier two [Member] Supplier two Credit Facility [Axis] Credit Facility [Axis] Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Inventory Valuation Reserves Inventory Valuation Reserves Inventory Disclosure [Text Block] Inventory Disclosure [Text Block] Long-Term Debt, Maturity, Year Five Long-Term Debt, Maturity, Year Five Accumulated Deficit [Member] Retained Earnings [Member] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Common Stock, Conversion Basis Common Stock, Conversion Basis Common Stock [Member] Common Stock [Member] Lease, Cost [Table Text Block] Lease, Cost [Table Text Block] Long-Term Debt, Maturity, after Year Five Long-Term Debt, Maturity, after Year Five Income Taxes Income Tax, Policy [Policy Text Block] Revenue Recognition Revenue [Policy Text Block] Statement [Table] Statement [Table] Long-term Debt EIDL loan and accrued interest EIDL Loan and Accrued Interest Document Quarterly Report Document Quarterly Report Current assets: Assets, Current [Abstract] Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Debt Instrument, Interest Rate During Period Debt Instrument, Interest Rate During Period Statistical Measurement [Axis] Statistical Measurement [Axis] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit) Convertible Preferred Stock, Shares Issued upon Conversion Convertible Preferred Stock, Shares Issued upon Conversion Other Operating Activities, Cash Flow Statement Other Operating Activities, Cash Flow Statement Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current schedule of inventory [Abstract] schedule of inventory [Abstract] schedule of inventory [Abstract] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Statement, Equity Components [Axis] Equity Components [Axis] Interest income Investment Income, Interest Dividends Payable, Date to be Paid Preferred Stock, Amount of Preferred Dividends in Arrears Accounts Payable Benchmark [Member] Accounts Payable Benchmark [Member] Accounts Payable Benchmark [Member] Related Party Transactions Related Party Transactions Disclosure [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Cash Flows from Operating Activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Other Notes Payable, Current Other Notes Payable, Current City Area Code City Area Code ASSETS Assets [Abstract] Statement [Line Items] Statement [Line Items] Impairment of Intangible Assets (Excluding Goodwill) Impairment of Intangible Assets (Excluding Goodwill) Cost of Goods and Service Benchmark Cost of Goods and Service Benchmark [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Line of Credit Facility, Periodic Payment, Interest Line of Credit Facility, Periodic Payment, Interest Deferred Revenue, Additions Deferred Revenue, Additions Nonoperating Income (Expense) Total other (expense) income Nonoperating Income (Expense) Variable Rate [Domain] Variable Rate [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Notes Payable to Banks [Member] Notes Payable to Banks [Member] Marketing, general and administrative Selling, General and Administrative Expense Line of credit Line of Credit, Current Customer One [Member] Customer One [Member] Customer One [Member] Deferred Revenue Deferred Revenue Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Net Cash provided by (used in) Financing Activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain] Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain] Product [Member] Product [Member] Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset Long-term Debt, Weighted Average Interest Rate, at Point in Time Long-Term Debt, Weighted Average Interest Rate, at Point in Time Net Income (loss) Per Share Earnings Per Share, Policy [Policy Text Block] Long-Term Debt, Maturity, Year One Long-Term Debt, Maturity, Year One Net present value of new lease future payments Net present value of new lease future payments Net present value of new lease future payments Deferred Revenue, Revenue Recognized Deferred Revenue, Revenue Recognized Variable Rate [Axis] Variable Rate [Axis] Other Liabilities, Noncurrent Other Liabilities, Noncurrent Repayment of EIDL loan Repayment of EIDL loan Repayment of EIDL loan Accounts Receivable Benchmark [Member] Accounts Receivable Benchmark [Member] Accounts Receivable Benchmark [Member] Document Transition Report Document Transition Report Increase (Decrease) in Other Operating Liabilities Increase (Decrease) in Other Operating Liabilities Local Phone Number Local Phone Number Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Loss from operations Operating Income (Loss) Increase (Decrease) in Inventories Increase (Decrease) in Inventories New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Line of Credit Facility, Interest Rate at Period End Line of Credit Facility, Interest Rate at Period End Short-term Lease Payments Short-Term Lease Payments Common stock, shares outstanding Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding Inventory, Gross Inventory, Gross Service [Member] Service [Member] Customer [Domain] Customer [Domain] EX-101.PRE 10 esmc-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - shares
 3 Months Ended
Sep. 30, 2022
Nov. 10, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Entity Registrant Name Escalon Medical Corp.  
Entity Incorporation, State or Country Code PA  
Entity Tax Identification Number 33-0272839  
Entity Address, Address Line One 435 Devon Park Drive  
Entity Address, City or Town Wayne  
Document Transition Report false  
Entity File Number 000-20127  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 19087  
City Area Code (610)  
Local Phone Number 688-6830  
Entity Emerging Growth Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   7,415,329
Title of 12(b) Security common stock, $0.001 par value  
Entity Central Index Key 0000862668  
Current Fiscal Year End Date --06-30  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Balance Sheets - USD ($)
Sep. 30, 2022
Jun. 30, 2022
Current assets:    
Cash and cash equivalents $ 275,147 $ 593,869
Restricted Cash, Current 256,176 256,165
Accounts receivable, net 1,650,922 1,541,750
Inventory, net 1,617,000 1,603,955
Other current assets 216,540 190,043
Total current assets 4,015,785 4,185,782
Property and equipment, net 46,177 52,660
Operating Lease, Right-of-Use Asset 717,345 788,257
Finite-Lived Intangible Assets, Net 84,903 82,750
Deposits Assets, Noncurrent 62,788 62,788
Total assets 4,926,998 5,172,237
Current liabilities:    
Line of credit 201,575 201,575
Other Notes Payable, Current 3,401 3,401
Secured Debt, Current 2,888 3,105
Accounts payable 1,289,847 1,012,451
Accrued expenses 842,045 901,996
Interest Payable, Current 112,389 112,389
Operating Lease, Liability, Current 310,921 304,737
Deferred Revenue 274,118 332,383
Other short-term liabilities 120,861 129,961
Total current liabilities 3,158,045 3,001,998
Other Notes Payable, Noncurrent 3,201 3,888
Operating Lease, Liability, Noncurrent 459,190 538,794
Total long-term liabilities 611,660 692,222
Total liabilities 3,769,705 3,694,220
Shareholders equity:    
Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized;2,000,000 issued and outstanding 645,000 645,000
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding 7,415 7,415
Additional paid-in capital 69,702,043 69,702,043
Accumulated deficit (69,197,165) (68,876,441)
Total shareholders' equity 1,157,293 1,478,017
Total liabilities and shareholders' equity 4,926,998 5,172,237
Secured Debt [Member]    
Current liabilities:    
Secured Long-term Debt, Noncurrent $ 149,269 $ 149,540
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2022
Jun. 30, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 2,000,000 2,000,000
Preferred Stock, Shares Issued 2,000,000 2,000,000
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 35,000,000 35,000,000
Common stock, shares issued 7,415,329 7,415,329
Common stock, shares outstanding 7,415,329 7,415,329
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements Of Operations - USD ($)
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Revenue from External Customer [Line Items]    
Net Income (Loss) Available to Common Stockholders, Basic $ (333,730) $ 304,214
Revenues $ 2,604,816 $ 2,675,069
Weighted average shares - basic 7,415,329 7,415,329
Cost of Goods and Services Sold $ 1,548,372 $ 1,663,874
Research and development 264,241 291,189
Other Nonoperating Income (Expense) 0 506,305
Interest Expense 4,827 4,600
Loss from operations (315,897) (184,485)
Net (loss) income (320,724) 317,220
Preferred Stock Dividends, Income Statement Impact 13,006 13,006
Marketing, general and administrative 1,108,100 904,491
Costs and Expenses 2,920,713 2,859,554
Nonoperating Income (Expense) $ (4,827) $ 501,705
Earnings (Loss) Per Share, Basic $ (0.05) $ 0.04
Weighted Average Number of Shares Outstanding, Diluted 7,415,329 12,876,202
Earnings (Loss) Per Share, Diluted $ (0.05) $ 0.02
Costs and expenses:    
Cost of Goods and Services Sold $ 1,548,372 $ 1,663,874
Marketing, general and administrative 1,108,100 904,491
Research and development 264,241 291,189
Total costs and expenses 2,920,713 2,859,554
Loss from operations (315,897) (184,485)
Other (expense) income:    
Other Nonoperating Income (Expense) 0 506,305
Interest expense (4,827) (4,600)
Total other (expense) income (4,827) 501,705
Net (loss) income (320,724) 317,220
Preferred Stock Dividends, Income Statement Impact 13,006 13,006
Net Income (Loss) Available to Common Stockholders, Basic $ (333,730) $ 304,214
Net income (loss) per share    
Earnings (Loss) Per Share, Basic $ (0.05) $ 0.04
Earnings (Loss) Per Share, Diluted $ (0.05) $ 0.02
Weighted average shares - basic 7,415,329 7,415,329
Weighted Average Number of Shares Outstanding, Diluted 7,415,329 12,876,202
Geographic Concentration Risk [Member]    
Revenue from External Customer [Line Items]    
Revenues   $ 2,675,000
Revenue Benchmark [Member] | Geographic Concentration Risk [Member]    
Revenue from External Customer [Line Items]    
Revenues $ 2,605,000 2,675,000
International [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]    
Revenue from External Customer [Line Items]    
Revenues 985,000 1,050,000
Product [Member]    
Revenue from External Customer [Line Items]    
Revenue from Contract with Customer, Excluding Assessed Tax 2,442,337 2,479,777
Service [Member]    
Revenue from External Customer [Line Items]    
Revenue from Contract with Customer, Excluding Assessed Tax $ 162,479 $ 195,292
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements Of Shareholders' Equity and Comprehensive Loss - USD ($)
Total
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Balance at Jun. 30, 2021 $ 1,459,936     $ 69,702,043 $ (68,894,522)
Net (loss) income 317,220 $ 0 $ 0 0 317,220
Balance at Sep. 30, 2021 1,777,156     69,702,043 (68,577,302)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued 645,000   $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding $ 7,415 $ 7,415      
Common Stock, Shares, Outstanding 7,415,329 7,415,329      
Balance at Jun. 30, 2022 $ 1,478,017     69,702,043 (68,876,441)
Net (loss) income (320,724) $ 0 $ 0 0 (320,724)
Balance at Sep. 30, 2022 $ 1,157,293     $ 69,702,043 $ (69,197,165)
Preferred Stock, Shares Outstanding     2,000,000    
Convertible Preferred Stock, Shares Issued upon Conversion 2.15        
Preferred Stock, Value, Issued $ 645,000   $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding $ 7,415 $ 7,415      
Common Stock, Shares, Outstanding 7,415,329 7,415,329      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements Of Cash Flows - USD ($)
 3 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Cash Flows from Operating Activities:        
Net (loss) income $ (320,724) $ 317,220    
Accounts Receivable, Credit Loss Expense (Reversal) 5,000 15,000    
Other Noncash Income (Expense) 0 506,305    
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization 11,485 13,450    
us-gaap_OtherNonoperatingIncomeExpensenoncash 0 (506,305)    
Change in operating assets and liabilities:        
Increaser(Decrease) in Accounts Receivable (114,172) (291,148)    
Increase (Decrease) in Inventories (13,045) 28,929    
Increase (Decrease) in Other Operating Assets (26,497) (8,551)    
Increase (Decrease) in Deferred Revenue (58,265) (87,432)    
Increase (Decrease) in Accounts Payable 277,396 19,617    
Increase (Decrease) in Accrued Liabilities (59,951) 109,519    
Increase (Decrease) in Other Operating Liabilities (108,081) (70,303)    
Other Operating Activities, Cash Flow Statement 105,573 68,718    
Increase (Decrease) in Other Deferred Liability (9,100) (2,100)    
Net Cash Provided by (Used in) Operating Activities (310,381) (393,386)    
Cash Flows from Investing Activities:        
Payments to Acquire Intangible Assets (7,155) 0    
Net Cash Provided by (Used in) Investing Activities (7,155) 0    
Net Cash provided by (used in) Financing Activities:        
Repayments of Notes Payable (687) (958)    
Repayment of EIDL loan (488) (705)    
Net Cash Provided by (Used in) Financing Activities (1,175) (1,663)    
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (318,711) (395,049)    
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning of Period 850,034 1,906,890 $ 1,906,890  
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, End of Period 531,323 1,511,841 850,034  
Cash and cash equivalents 275,147 1,255,824 593,869 $ 1,650,970
Restricted Cash 256,176 256,017 256,165 255,920
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 531,323 1,511,841 $ 850,034 $ 1,906,890
Supplemental Schedule of Cash Flow Information:        
Interest Paid, Excluding Capitalized Interest, Operating Activities $ 5,273 $ 4,697    
Weighted average shares - basic 7,415,329 7,415,329    
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Description of Business
 3 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Description of Business and Business Conditions Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc.
    The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.

    The unaudited condensed consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, and reflect all adjustments (consisting of only normal and recurring adjustments) which are, in the opinion of management, necessary to present fairly the unaudited condensed consolidated financial information required herein. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United Statements of America ("US GAAP") have been condensed or omitted pursuant to such rules and regulations. While management believes that the disclosures are adequate to make the information presented not misleading, it is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed with the Security and Exchange Commission for the fiscal year ended June 30, 2022. The results of operations for the three months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full year.

In February 2022, Russia invaded Ukraine. As military activity proceeds and sanctions, export controls and other measures are imposed by many countries against Russia, Belarus and specific areas of Ukraine, the war is increasingly affecting the global economy and financial markets, as well as exacerbating ongoing economic challenges, including rising inflation and global supply-chain disruption. The Company has operations or activities in countries and regions outside the United States. As a result, its global operations are affected by economic, political and other conditions in the foreign countries in which the Company has business as well as U.S. laws regulating international trade, although the Company has not yet assessed that the war has had a material effect on its financial position or results of operations. The Company will continue to monitor the impacts of the Russia-Ukraine war on macroeconomic conditions and continually assess the effect these matters may have on customer demand, suppliers’ ability to deliver products, cybersecurity risks and its liquidity and access to capital.

    The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Going concern (Notes)
 3 Months Ended
Sep. 30, 2022
Going concern [Abstract]  
Liquidity Disclosure [Policy Text Block] . Going Concern
The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the continuous enhancement of the current products, development of new products; changes in domestic and foreign regulations; ability of manufacture successfully; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products and its ability to raise capital to support its operations.

To date, the Company’s operations have not generated sufficient revenues to enable profitability. As of September 30, 2022, the Company had an accumulated deficit of $69.2 million, and incurred recurring losses from operations and incurred negative cash flows from operating activities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for the next 12 months following the issuance of these unaudited condensed consolidated financial statements.

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
The Company's continuance as a going concern is dependent on its future profitability and on the on-going support of its shareholders, affiliates and creditors. In order to mitigate the going concern issues, the Company is actively pursuing business partnerships, managing its continuing operations, implementing cost-cutting measures and seeking to sell certain assets. The Company may not be successful in any of these efforts.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies
 3 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Significant Accounting Policies Summary of Accounting Policies
Quarterly Reporting
The accompanying unaudited condensed consolidated financial statements (“financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and have been consistently applied. Certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP, but which are not required for interim reporting purposes, have been omitted. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to present fairly the financial position as of September 30, 2022 and the results of operations and cash flows for the interim periods ended September 30, 2022 and 2021, have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended June 30, 2022 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on September 28, 2022. Operating results for the three months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the full year ending June 30, 2023.
Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable

Accounts receivable are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company recorded an allowance for doubtful accounts of approximately $241,000 and $236,000 as of September 30, 2022 and June 30, 2022, respectively.

Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the Company’s forecasts of future sales and age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely impact the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year.

PPP Loans
    The Company's policy is to account for the PPP loan (See Note 7) as debt. The Company will continue to record the loan as debt until either (1) the loan is partially or entirely forgiven and the Company has been legally released, at which point the amount forgiven will be recorded as income or (2) the Company pays off the loan. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021 and was included in other income in the unaudited condensed consolidated income statement for the three-month period ended September 30, 2021.

Deferred Revenues

    The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plans for a 12-month period. The consideration received is recognized monthly over the service period.

(in thousands)Three Months Ended September 30,
20222021
Beginning of Period$332 $364 
Additions104107
Revenue Recognized162 195 
End of Period$274 $276 

(Loss) earnings Per Share    
(Loss) earnings per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of September 30, 2022, and 2021, the average market prices for the three-month periods then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three-month periods ended September 30, 2022. Therefore, basic and diluted loss per common share for the three-month periods ended September 30, 2022 are the same.
For the Three Months Ended September 30,
20222021
Numerator:
  Numerator for basic loss per share:
 Net (loss) income$(320,724)$317,220 
Undeclared dividends on preferred stock$13,006 13,006 
Net (loss) income applicable to common shareholders$(333,730)$304,214 
Numerator for diluted earnings per share:
Net (loss) income applicable to common shareholders$(333,730)$304,214 
Undeclared dividends on preferred stock13,006 13,006 
Diluted (loss) income$(320,724)$317,220 
Denominator for basic (loss) earnings per share
Denominator for basic (loss) earnings per share - weighted average shares outstanding
7,415,3297,415,329 
Weighted average preferred stock converted to common stock— 5,460,873 
 Denominator for diluted (loss) earnings assumed conversion7,415,329 12,876,202 
Net (loss) earnings per share:
Basic net (loss) earnings per share$(0.05)$0.04 
Diluted net (loss) earnings per share$(0.05)$0.02 

The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.
For the Three Months Ended September 30,
20222021
Stock options157,000 157,000 
Convertible preferred stock5,891,580 — 
Total potential dilutive securities not included in income per share6,048,580 157,000 

Income Taxes

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of September 30, 2022 and June 30, 2022, the Company has a fully recorded valuation allowance against its deferred tax assets.

    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of September 30, 2022 and June 30, 2022, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited condensed consolidated balance sheets.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventory (Notes)
 3 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Inventory Disclosure [Text Block] Inventories
September 30,
June 30,
(in thousands)20222022
Inventories:
        Raw Material$1,028 $1,010 
        Work-In-Process154 138 
        Finished Goods785 806 
Total inventories$1,967 $1,954 
Allowance for obsolete inventory(350)(350)
Inventories, net$1,617 $1,604 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long term debt (Notes)
 3 Months Ended
Sep. 30, 2022
Debt Instrument [Line Items]  
Long-term Debt [Text Block]
Paycheck Protection Program ("PPP") loan

    On April 27, 2020, the Company entered into a PPP loan for $500,000 in connection with the CARES Act related to COVID-19. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021 and was included in other income in the unaudited condensed consolidated statement of operations for the three-month period ended September 30, 2021.

Economic Injury Disaster ("EIDL") Loan

    EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal
operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received a $150,000 EIDL loan. The annual interest rate is 3.75%. The payment term is 30 years and the monthly payment of $731 started on July 1st, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company.

    The future annual principal amounts to be paid as of September 30, 2022 are as follows:
Year ending June 30,EIDL Payment
2023 (remainder of FY 2023)2,631 
20243,237 
20253,376 
20263,497 
Thereafter139,416 
Total$152,157 

Other short-term Liabilities
    The CARES Act allows employers to defer the deposit and payment of the employer share of Social Security tax that would otherwise be due on or after March 27, 2020, and before January 1, 2021. The Company had deferred approximately $82,000 of the social security tax. 50% of the deferred employment taxes was paid before December 31, 2021. The remaining 50% is not due until December 31, 2022. Approximately $41,000 was reported as short-term other liabilities as of September 30, 2022.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions
 3 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions and Preferred Stock    On February 14, 2018, the Company entered into a Debt Exchange Agreement (the “Exchange Agreement”) with Richard DePiano, Sr., (Mr. DePiano Sr.), the Company's former Chairman and DP Associates Inc. Profit-Sharing Plan of
which Mr. DePiano Sr. is the sole owner and sole trustee (the “Holders”).  Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program the Company owes the Holders for 2,000,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”).
    
    Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders.  As a result of this voting power, the Holders as September 30, 2022 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company’s shareholders.

    Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the “Conversion Ratio”).  The Conversion Ratio is subject to standard provisions for adjustment in the event of a subdivision or combination of the Company’s Common Stock and upon any reorganization or reclassification of the capital stock of the Company. If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the then outstanding shares of Common Stock assuming such conversion.

    Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock. Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full. The dividends payable to the holders of the Preferred Stock is payable in cash or, at the election of any such holder, in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then applicable Conversion Ratio, described above. As of September 30, 2022 and June 30, 2022 the cumulative dividends payable is $238,737 ($0.1194 per share) and $225,731 ($0.1129 per share), respectively.

    Mr. DePiano Sr. passed away on October 3, 2019 and left a will by which he appointed Richard J. DePiano, Jr., the Chief Executive Officer of the Company, as executor. Richard DePiano Jr. was elected to serve as chairman of the Company's board. Mr. DePiano, Jr. qualified as executor and has control over the listed shares in his capacity as executor of Mr. DePiano Sr.'s estate.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Line of credit (Notes)
 3 Months Ended
Sep. 30, 2022
Line of Credit Facility [Line Items]  
Debt Disclosure [Text Block] On June 29, 2018 the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.0% per annum. Interest on the unpaid principal balance of the note is calculated using a rate of 0.74 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.74% per annum based on a year of 360 days. The interest rate was 6.54% as of September 30, 2022. The Company was required to put $250,000 in the TD bank savings account as collateral. The Loan is now guaranteed by Mr. DePiano Jr.     As of September 30, 2022 and June 30, 2022, the line of credit balance was $201,575 with TD bank. The line of credit interest expense was approximately $3,000 for the three months ended September 30, 2022 and 2021, respectively.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Concentration of credit risk (Notes)
 3 Months Ended
Sep. 30, 2022
Concentration Risk [Line Items]  
Concentration Risk Disclosure [Text Block]
Credit Risk

Financial instruments, which potentially subject the Company to concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely address the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral.

Major Customer

    No customer accounted for more than 10% of net sales during the three-month period ended September 30, 2022. One customer accounted for 13% during the three-month period ended September 30, 2021.

    As of September 30, 2022 the Company had one customer that represented 11% of the total accounts receivable balance. As of June 30, 2022 the Company had one customer that represents 13% of the total accounts receivable balance.

Major Supplier

    The Company's one largest supplier accounted for 38% of the total purchase for the three-month period ended September 30, 2022. The Company's three largest suppliers accounted for 32%, 13% and 11% of total purchases for the three-month period ended September 30, 2021.

    As of September 30, 2022 the Company had two supplier that represented 33% and 13% of the total accounts payable balance. As of June 30, 2022 the Company had one suppliers that represent approximately 36% of the total accounts payable balance.
Disaggregated Revenue

    Domestic and international sales from operations are as follows:
( in thousands)For the Three Months Ended September 30,
20222021
Domestic$1,620 62.2 %$1,625 60.7 %
Foreign985 37.8 %$1,050 39.3 %
Total$2,605 100 %$2,675 100 %
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Notes)
 3 Months Ended
Sep. 30, 2022
Lessee Disclosure [Abstract]  
Lease Leases
    The Company leases certain facilities and equipment under operating leases. Total lease expense, under ASC 842, was included in cost of goods sold and marketing, general and administrative costs in our unaudited condensed consolidated statements of operations for the three months ended September 30, 2022 and 2021 as follows:

Three Months Ended September 30,
20222021
Operating lease costs:
Fixed$85,436 $84,245 
Total:$85,436 $84,245 

    Supplemental cash flow information was as follows:
Three Months Ended September 30,
20222021
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases$84,592 $82,390 
Total$84,592 $82,390 


    The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate)
under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheets as of September 30, 2022:
Operating
2023 (reminder of FY 2023)258,649 
2024350,142 
2025211,215 
20262,728 
Total lease payments822,734 
Less interest 52,622 
Present value of lease liabilities$770,112 

    Average lease terms and discount rates were as follows:
September 30, June 30,
20222022
Weighted-average remaining lease terms (years)
Operating leases
2.362.61
Weighted-average discount rate
Operating leases
5.65 %5.65 %
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies (Policies)
 3 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition
Deferred Revenues

    The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plans for a 12-month period. The consideration received is recognized monthly over the service period.

(in thousands)Three Months Ended September 30,
20222021
Beginning of Period$332 $364 
Additions104107
Revenue Recognized162 195 
End of Period$274 $276 
Inventory Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the Company’s forecasts of future sales and age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely impact the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year.
Accounts Receivable Accounts receivable are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company recorded an allowance for doubtful accounts of approximately $241,000 and $236,000 as of September 30, 2022 and June 30, 2022, respectively.
Loan Commitments, Policy The Company's policy is to account for the PPP loan (See Note 7) as debt. The Company will continue to record the loan as debt until either (1) the loan is partially or entirely forgiven and the Company has been legally released, at which point the amount forgiven will be recorded as income or (2) the Company pays off the loan. The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021 and was included in other income in the unaudited condensed consolidated income statement for the three-month period ended September 30, 2021.
Net Income (loss) Per Share (Loss) earnings per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of September 30, 2022, and 2021, the average market prices for the three-month periods then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three-month periods ended September 30, 2022. Therefore, basic and diluted loss per common share for the three-month periods ended September 30, 2022 are the same.
For the Three Months Ended September 30,
20222021
Numerator:
  Numerator for basic loss per share:
 Net (loss) income$(320,724)$317,220 
Undeclared dividends on preferred stock$13,006 13,006 
Net (loss) income applicable to common shareholders$(333,730)$304,214 
Numerator for diluted earnings per share:
Net (loss) income applicable to common shareholders$(333,730)$304,214 
Undeclared dividends on preferred stock13,006 13,006 
Diluted (loss) income$(320,724)$317,220 
Denominator for basic (loss) earnings per share
Denominator for basic (loss) earnings per share - weighted average shares outstanding
7,415,3297,415,329 
Weighted average preferred stock converted to common stock— 5,460,873 
 Denominator for diluted (loss) earnings assumed conversion7,415,329 12,876,202 
Net (loss) earnings per share:
Basic net (loss) earnings per share$(0.05)$0.04 
Diluted net (loss) earnings per share$(0.05)$0.02 

The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.
For the Three Months Ended September 30,
20222021
Stock options157,000 157,000 
Convertible preferred stock5,891,580 — 
Total potential dilutive securities not included in income per share6,048,580 157,000 

Income Taxes

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of September 30, 2022 and June 30, 2022, the Company has a fully recorded valuation allowance against its deferred tax assets.

    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of September 30, 2022 and June 30, 2022, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited condensed consolidated balance sheets.
New Accounting Pronouncements
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies (Tables)
 3 Months Ended 12 Months Ended
Sep. 30, 2022
Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.
For the Three Months Ended September 30,
20222021
Stock options157,000 157,000 
Convertible preferred stock5,891,580 — 
Total potential dilutive securities not included in income per share6,048,580 157,000 

Income Taxes

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of September 30, 2022 and June 30, 2022, the Company has a fully recorded valuation allowance against its deferred tax assets.

    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of September 30, 2022 and June 30, 2022, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited condensed consolidated balance sheets.
  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]  
For the Three Months Ended September 30,
20222021
Numerator:
  Numerator for basic loss per share:
 Net (loss) income$(320,724)$317,220 
Undeclared dividends on preferred stock$13,006 13,006 
Net (loss) income applicable to common shareholders$(333,730)$304,214 
Numerator for diluted earnings per share:
Net (loss) income applicable to common shareholders$(333,730)$304,214 
Undeclared dividends on preferred stock13,006 13,006 
Diluted (loss) income$(320,724)$317,220 
Denominator for basic (loss) earnings per share
Denominator for basic (loss) earnings per share - weighted average shares outstanding
7,415,3297,415,329 
Weighted average preferred stock converted to common stock— 5,460,873 
 Denominator for diluted (loss) earnings assumed conversion7,415,329 12,876,202 
Net (loss) earnings per share:
Basic net (loss) earnings per share$(0.05)$0.04 
Diluted net (loss) earnings per share$(0.05)$0.02 
Schedule of Inventory, Current [Table Text Block]
September 30,
June 30,
(in thousands)20222022
Inventories:
        Raw Material$1,028 $1,010 
        Work-In-Process154 138 
        Finished Goods785 806 
Total inventories$1,967 $1,954 
Allowance for obsolete inventory(350)(350)
Inventories, net$1,617 $1,604 
  
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]  
(in thousands)Three Months Ended September 30,
20222021
Beginning of Period$332 $364 
Additions104107
Revenue Recognized162 195 
End of Period$274 $276 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventory (Tables)
 3 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current [Table Text Block]
September 30,
June 30,
(in thousands)20222022
Inventories:
        Raw Material$1,028 $1,010 
        Work-In-Process154 138 
        Finished Goods785 806 
Total inventories$1,967 $1,954 
Allowance for obsolete inventory(350)(350)
Inventories, net$1,617 $1,604 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long term debt (Tables)
 3 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Maturities of Long-term Debt [Table Text Block]
Year ending June 30,EIDL Payment
2023 (remainder of FY 2023)2,631 
20243,237 
20253,376 
20263,497 
Thereafter139,416 
Total$152,157 
Contractual Obligation, Fiscal Year Maturity The future annual principal amounts to be paid as of September 30, 2022 are as follows:
Year ending June 30,EIDL Payment
2023 (remainder of FY 2023)2,631 
20243,237 
20253,376 
20263,497 
Thereafter139,416 
Total$152,157 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Concentration of credit risk (Tables)
 3 Months Ended
Sep. 30, 2022
Concentration of credit risks [Abstract]  
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Domestic and international sales from operations are as follows:
( in thousands)For the Three Months Ended September 30,
20222021
Domestic$1,620 62.2 %$1,625 60.7 %
Foreign985 37.8 %$1,050 39.3 %
Total$2,605 100 %$2,675 100 %
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Tables) - USD ($)
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Lessee Disclosure [Abstract]    
Lease, Cost [Table Text Block]
Three Months Ended September 30,
20222021
Operating lease costs:
Fixed$85,436 $84,245 
Total:$85,436 $84,245 
Three Months Ended September 30,
20222021
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases$84,592 $82,390 
Total$84,592 $82,390 
September 30, June 30,
20222022
Weighted-average remaining lease terms (years)
Operating leases
2.362.61
Weighted-average discount rate
Operating leases
5.65 %5.65 %
  
Short-term Lease Payments $ 84,592 $ 82,390
Lessee, Operating Lease, Liability, Maturity
Operating
2023 (reminder of FY 2023)258,649 
2024350,142 
2025211,215 
20262,728 
Total lease payments822,734 
Less interest 52,622 
Present value of lease liabilities$770,112 
  
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Going concern (Details) - USD ($)
Sep. 30, 2022
Jun. 30, 2022
Going concern [Abstract]    
Retained Earnings (Accumulated Deficit) $ (69,197,165) $ (68,876,441)
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies (Cash and Cash Equivalents) (Details) - USD ($)
Sep. 30, 2022
Jun. 30, 2022
Sep. 30, 2021
Jun. 30, 2021
Accounting Policies [Abstract]        
Restricted Cash $ 256,176 $ 256,165 $ 256,017 $ 255,920
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies (Inventory) (Details) - USD ($)
Sep. 30, 2022
Jun. 30, 2022
schedule of inventory [Abstract]    
Inventory, net $ 1,617,000 $ 1,603,955
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies (Accounts Receivable) (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Jun. 30, 2022
Accounting Policies [Abstract]    
Accounts Receivable, Allowance for Credit Loss $ 241 $ 236
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies (Net Income (loss) Per Share) (Details) - USD ($)
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Net (loss) income $ (320,724) $ 317,220
Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic $ (333,730) $ 304,214
Basic Weighted average shares outstanding 7,415,329 7,415,329
Weighted Average Number of Shares Outstanding, Diluted 7,415,329 12,876,202
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies Earning per share details (Details) - USD ($)
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Net (loss) income $ (320,724) $ 317,220
Preferred Stock Dividends, Income Statement Impact 13,006 13,006
Net Income (Loss) Available to Common Stockholders, Diluted $ (320,724) $ 317,220
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6,048,580 157,000
Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic $ (333,730) $ 304,214
Convertible Preferred Dividends, Net of Tax $ 13,006  
Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities   $ 13,006
Weighted average shares - basic 7,415,329 7,415,329
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 0 5,460,873
Weighted average shares - diluted 7,415,329 12,876,202
Earnings (Loss) Per Share, Basic $ (0.05) $ 0.04
Earnings (Loss) Per Share, Diluted $ (0.05) $ 0.02
Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 157,000 157,000
Equity Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 5,891,580 0
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies deferred revenue (Details) - USD ($)
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue Recognition and Deferred Revenue [Abstract]        
Deferred Revenue $ 274,118 $ 276,000 $ 332,383 $ 364,000
Deferred Revenue, Additions 104,000 107,000    
Deferred Revenue, Revenue Recognized $ 162,000 $ 195,000    
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies New accounting pronouncements recently adopted (Details) - USD ($)
Sep. 30, 2022
Jun. 30, 2022
New accounting pronouncements recently adopted [Abstract]    
Operating Lease, Right-of-Use Asset $ 717,345 $ 788,257
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventory (Details) - USD ($)
Sep. 30, 2022
Jun. 30, 2022
Inventory Disclosure [Abstract]    
Inventory, net $ 1,617,000 $ 1,603,955
Inventory, Raw Materials, Gross 1,028,000 1,010,000
Inventory, Work in Process, Gross 154,000 138,000
Inventory, Finished Goods, Gross 785,000 806,000
Inventory Valuation Reserves (350,000) (350,000)
Inventory, Gross $ 1,967,000 $ 1,954,000
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long term debt (Details) - USD ($)
 3 Months Ended
Sep. 30, 2022
Mar. 31, 2022
Debt Instrument [Line Items]    
Debt Instrument, Periodic Payment $ 731  
Other Long-term Debt 82,000  
Other Short-term Borrowings 41,000  
Secured Debt [Member]    
Debt Instrument [Line Items]    
Long-term Debt $ 150,000  
Secured Debt [Member]    
Debt Instrument [Line Items]    
Long-term Debt, Weighted Average Interest Rate, at Point in Time 3.75%  
Long-Term Debt, Maturity, after Year Five $ 139,416  
Long-Term Debt, Maturity, Year Two 2,631  
Long-Term Debt, Maturity, Year Three 3,237  
Long-Term Debt, Maturity, Year Four 3,376  
Long-Term Debt, Maturity, Year Five 3,497  
Long-term Debt $ 152,157  
Payroll Protection Program Loan [Member]    
Debt Instrument [Line Items]    
Long-term Debt, Current Maturities   $ 500,000
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions (Details) - USD ($)
 3 Months Ended 6 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Jun. 30, 2022
Feb. 14, 2018
Related Party Transaction [Line Items]        
Related Party Transaction, Due from (to) Related Party       $ 645,000
Preferred Stock, Shares Issued 2,000,000   2,000,000 2,000,000
Common Stock, Voting Rights 77.81      
Convertible Preferred Stock, Shares Issued upon Conversion 2.15      
Common Stock, Conversion Basis 4,300,000      
Dividends Payable, Date to be Paid $ 238,737 $ 225,731    
Dividends Payable, Amount Per Share $ (0.1194)   $ (0.1129) $ (0.0258)
Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion 36.70%      
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Line of credit (Details) - USD ($)
 3 Months Ended 6 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2022
Jun. 30, 2022
Jun. 29, 2018
Line of Credit Facility [Line Items]          
Line of Credit Facility, Periodic Payment, Interest $ 3,000        
Line of Credit Facility, Interest Rate at Period End 6.54%        
Accrued expenses $ 842,045     $ 901,996  
Interest Expense 4,827 $ 4,600      
Line of credit $ 201,575     $ 201,575  
Customer One [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]          
Line of Credit Facility [Line Items]          
Concentration Risk, Percentage 13.00%        
Notes Payable to Banks [Member]          
Line of Credit Facility [Line Items]          
Notes Payable to Bank         $ 250,000
Debt Instrument, Interest Rate, Stated Percentage         5.00%
Debt Instrument, Basis Spread on Variable Rate     74.00%    
Debt Instrument, Interest Rate During Period     5.74%    
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Concentration of credit risk (Details) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Jun. 30, 2022
Concentration Risk [Line Items]        
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Domestic and international sales from operations are as follows:
( in thousands)For the Three Months Ended September 30,
20222021
Domestic$1,620 62.2 %$1,625 60.7 %
Foreign985 37.8 %$1,050 39.3 %
Total$2,605 100 %$2,675 100 %
      
Revenues $ 2,604,816 $ 2,675,069    
Customer Concentration Risk [Member] | Customer One [Member]        
Concentration Risk [Line Items]        
Concentration Risk, Customer No One    
Geographic Concentration Risk [Member]        
Concentration Risk [Line Items]        
Revenues   $ 2,675,000    
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]        
Concentration Risk [Line Items]        
Concentration Risk, Percentage 13.00%      
Revenue Benchmark [Member] | Geographic Concentration Risk [Member]        
Concentration Risk [Line Items]        
Concentration Risk, Percentage 100.00% 100.00%    
Revenues $ 2,605,000 $ 2,675,000    
Accounts Payable Benchmark [Member] | Supplier Concentration Risk [Member]        
Concentration Risk [Line Items]        
Concentration Risk, Supplier two   one  
Accounts Receivable Benchmark [Member]        
Concentration Risk [Line Items]        
Concentration Risk, Customer one      
Accounts Receivable        
Concentration Risk [Line Items]        
Concentration Risk, Customer one three   one
Accounts Receivable | Customer Concentration Risk [Member] | Customer One [Member]        
Concentration Risk [Line Items]        
Concentration Risk, Percentage 11.00%     13.00%
Domestic [Member] | Geographic Concentration Risk [Member]        
Concentration Risk [Line Items]        
Revenues   $ 1,625,000    
Domestic [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]        
Concentration Risk [Line Items]        
Concentration Risk, Percentage 62.20% 60.70%    
Revenues   $ 1,625,000    
International [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]        
Concentration Risk [Line Items]        
Concentration Risk, Percentage 37.80% 39.30%    
Revenues $ 985,000 $ 1,050,000    
Supplier one [Member] | Revenue Benchmark [Member] | Supplier Concentration Risk [Member]        
Concentration Risk [Line Items]        
Concentration Risk, Percentage 38.00% 32.00%    
Supplier one [Member] | Accounts Payable Benchmark [Member] | Supplier Concentration Risk [Member]        
Concentration Risk [Line Items]        
Concentration Risk, Percentage 33.00%     36.00%
Supplier two [Member] | Revenue Benchmark [Member] | Supplier Concentration Risk [Member]        
Concentration Risk [Line Items]        
Concentration Risk, Percentage   13.00%    
Supplier two [Member] | Accounts Payable Benchmark [Member] | Supplier Concentration Risk [Member]        
Concentration Risk [Line Items]        
Concentration Risk, Percentage 13.00%      
Supplier three [Member] | Revenue Benchmark [Member] | Supplier Concentration Risk [Member]        
Concentration Risk [Line Items]        
Concentration Risk, Percentage   11.00%    
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Details) - USD ($)
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2023
Jun. 30, 2022
Lessee, Lease, Description [Line Items]        
Short-term Lease Payments $ 84,592 $ 82,390    
Net present value of new lease future payments $ 770,112      
Operating Lease, Weighted Average Remaining Lease Term 2 years 4 months 9 days     2 years 7 months 9 days
Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year      
Finance Lease, Liability, to be Paid, Year Two 258,649      
Operating Lease, Right-of-Use Asset 717,345     $ 788,257
Finance Lease, Liability, to be Paid, Year Three 350,142      
Finance Lease, Liability, to be Paid, Year Four 211,215      
Finance Lease, Liability, to be Paid, Year Five 2,728      
Operating Leases, Future Minimum Payments Due 822,734      
Interest portion in the future lease payments $ 52,622      
Operating Lease, Weighted Average Discount Rate, Percent 5.65%   5.65%  
Operating Lease, Liability, Current $ 310,921     304,737
Operating Lease, Liability, Noncurrent 459,190     $ 538,794
Operating Lease, Cost $ 85,436 $ 84,245    
XML 46 esmc-20220930_htm.xml IDEA: XBRL DOCUMENT 0000862668 2022-07-01 2022-09-30 0000862668 2022-11-10 0000862668 2022-09-30 0000862668 2022-06-30 0000862668 us-gaap:SecuredDebtMember 2022-09-30 0000862668 us-gaap:SecuredDebtMember 2022-06-30 0000862668 us-gaap:ProductMember 2022-07-01 2022-09-30 0000862668 us-gaap:ProductMember 2021-07-01 2021-09-30 0000862668 us-gaap:ServiceMember 2022-07-01 2022-09-30 0000862668 us-gaap:ServiceMember 2021-07-01 2021-09-30 0000862668 2021-07-01 2021-09-30 0000862668 us-gaap:PreferredStockMember 2022-06-30 0000862668 us-gaap:CommonStockMember 2022-06-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000862668 us-gaap:RetainedEarningsMember 2022-06-30 0000862668 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0000862668 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000862668 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000862668 us-gaap:PreferredStockMember 2022-09-30 0000862668 us-gaap:CommonStockMember 2022-09-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000862668 us-gaap:RetainedEarningsMember 2022-09-30 0000862668 us-gaap:PreferredStockMember 2021-06-30 0000862668 us-gaap:CommonStockMember 2021-06-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000862668 us-gaap:RetainedEarningsMember 2021-06-30 0000862668 2021-06-30 0000862668 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0000862668 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000862668 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000862668 us-gaap:PreferredStockMember 2021-09-30 0000862668 us-gaap:CommonStockMember 2021-09-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000862668 us-gaap:RetainedEarningsMember 2021-09-30 0000862668 2021-09-30 0000862668 2022-12-31 0000862668 2022-07-01 2023-06-30 0000862668 us-gaap:ConvertiblePreferredStockMember 2022-07-01 2022-09-30 0000862668 us-gaap:ConvertiblePreferredStockMember 2021-07-01 2021-09-30 0000862668 us-gaap:StockOptionMember 2022-07-01 2022-09-30 0000862668 us-gaap:StockOptionMember 2021-07-01 2021-09-30 0000862668 2018-02-14 0000862668 2021-07-01 2021-12-31 0000862668 us-gaap:NotesPayableToBanksMember 2018-06-29 0000862668 us-gaap:NotesPayableToBanksMember 2022-07-01 2022-12-31 0000862668 esmc:PayrollProtectionProgramLoanMember 2022-03-31 0000862668 us-gaap:SecuredDebtMember 2022-09-30 0000862668 esmc:CustomerOneMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000862668 esmc:CustomerOneMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000862668 esmc:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000862668 esmc:AccountsReceivableBenchmarkMember 2022-07-01 2022-09-30 0000862668 esmc:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000862668 us-gaap:AccountsReceivableMember 2021-07-01 2022-06-30 0000862668 esmc:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2022-06-30 0000862668 us-gaap:AccountsReceivableMember 2022-07-01 2022-09-30 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2022-07-01 2022-09-30 0000862668 us-gaap:AccountsReceivableMember 2021-07-01 2021-09-30 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2021-07-01 2021-09-30 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplierTwoMember 2021-07-01 2021-09-30 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplierthreeMember 2021-07-01 2021-09-30 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember 2022-07-01 2022-09-30 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2022-07-01 2022-09-30 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember esmc:SupplierTwoMember 2022-07-01 2022-09-30 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember 2021-07-01 2021-12-31 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2021-07-01 2022-06-30 0000862668 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2022-09-30 0000862668 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000862668 country:US us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000862668 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2022-09-30 0000862668 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000862668 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2022-09-30 0000862668 us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000862668 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000862668 2023-06-30 shares iso4217:USD iso4217:USD shares pure Escalon Medical Corp. 0000862668 --06-30 10-Q true 2022-09-30 2023 Q1 false true false false 7415329 false 000-20127 0.001 0.001 35000000 35000000 7415329 7415329 7415329 7415329 0.001 0.001 2000000 2000000 2000000 2000000 10-Q Escalon Medical Corp. PA 33-0272839 435 Devon Park Drive Wayne PA 19087 (610) 688-6830 Yes Yes Non-accelerated Filer true false common stock, $0.001 par value 275147 593869 256176 256165 1650922 1541750 1617000 1603955 216540 190043 4015785 4185782 46177 52660 717345 788257 84903 82750 62788 62788 4926998 5172237 201575 201575 3401 3401 2888 3105 1289847 1012451 842045 901996 112389 112389 310921 304737 274118 332383 120861 129961 3158045 3001998 3201 3888 149269 149540 459190 538794 611660 692222 3769705 3694220 645000 645000 7415 7415 69702043 69702043 -69197165 -68876441 1157293 1478017 4926998 5172237 2442337 2479777 162479 195292 2604816 2675069 1548372 1663874 1108100 904491 264241 291189 2920713 2859554 -315897 -184485 0 506305 4827 4600 -4827 501705 -320724 317220 13006 13006 -333730 304214 -0.05 0.04 -0.05 0.02 7415329 7415329 7415329 12876202 2000000 645000 7415329 7415 69702043 -68876441 1478017 0 0 0 0 0 -320724 -320724 2000000 645000 7415329 7415 69702043 -69197165 1157293 2000000 645000 7415329 7415 69702043 -68894522 1459936 0 0 0 0 0 317220 317220 2000000 645000 7415329 7415 69702043 -68577302 1777156 -320724 -320724 -320724 317220 317220 317220 5000 15000 0 -506305 11485 13450 105573 68718 114172 291148 13045 -28929 26497 8551 277396 19617 -59951 109519 -108081 -70303 -58265 -87432 -9100 -2100 -310381 -393386 7155 0 -7155 0 687 958 488 705 -1175 -1663 -318711 -395049 850034 1906890 531323 1511841 275147 1255824 256176 256017 531323 1511841 593869 1650970 256165 255920 850034 1906890 5273 4697 Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The unaudited condensed consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, and reflect all adjustments (consisting of only normal and recurring adjustments) which are, in the opinion of management, necessary to present fairly the unaudited condensed consolidated financial information required herein. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United Statements of America ("US GAAP") have been condensed or omitted pursuant to such rules and regulations. While management believes that the disclosures are adequate to make the information presented not misleading, it is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed with the Security and Exchange Commission for the fiscal year ended June 30, 2022. The results of operations fo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r the three months e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nded September 30, 2022 are not necessarily indicative of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the results to be expected for the full year. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia invaded Ukraine. As military activity proceeds and sanctions, export controls and other measures are imposed by many countries against Russia, Belarus and specific areas of Ukraine, the war is increasingly affecting the global economy and financial markets, as well as exacerbating ongoing economic challenges, including rising inflation and global supply-chain disruption. The Company has operations or activities in countries and regions outside the United States. As a result, its global operations are affected by economic, political and other conditions in the foreign countries in which the Company has business as well as U.S. laws regulating international trade, although the Company has not yet assessed that the war has had a material effect on its financial position or results of operations. The Company will continue to monitor the impacts of the Russia-Ukraine war on macroeconomic conditions and continually assess the effect these matters may have on customer demand, suppliers’ ability to deliver products, cybersecurity risks and its liquidity and access to capital.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”</span></div> . Going Concern<div style="padding-left:6.75pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the continuous enhancement of the current products, development of new products; changes in domestic and foreign regulations; ability of manufacture successfully; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products and its ability to raise capital to support its operations.</span></div><div style="margin-top:0.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:9pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company’s operations have not generated sufficient revenues to enable profitability. As of September 30, 2022, the Company had an accumulated deficit of $69.2 million, and incur</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">red recurring losses from operations and incurred negative cash flows from operating activities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for the next 12 months following the issuance of these unaudited condensed consolidated financial statements.</span></div><div style="padding-left:6.75pt;padding-right:9pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div>The Company's continuance as a going concern is dependent on its future profitability and on the on-going support of its shareholders, affiliates and creditors. In order to mitigate the going concern issues, the Company is actively pursuing business partnerships, managing its continuing operations, implementing cost-cutting measures and seeking to sell certain assets. The Company may not be successful in any of these efforts. -69200000 Summary of Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Quarterly Reporting</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements (“financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and have been consistently applied. Certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP, but which are not required for interim reporting purposes, have been omitted. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to present fairly the financial position as of September 30, 2022 and the results of operations and cash flows for the interim periods ended September 30, 2022 and 2021, have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended June 30, 2022 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on September 28, 2022. Operating results for the three months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the full year ending June 30, 2023.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company recorded an allowance for doubtful accounts of approximately $241,000 and $236,000 as of September 30, 2022 and June 30, 2022, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the Company’s forecasts of future sales and age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely impact the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year.</span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PPP Loans </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's policy is to account for the PPP loan</span><span style="background-color:#ffffff;color:#001f5e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(See Note 7)</span><span style="background-color:#ffffff;color:#001f5e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as debt. The Company will continue to record the loan as debt until either (1) the loan is partially or entirely forgiven and the Company has been legally released</span><span style="background-color:#ffffff;color:#001f5e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at which point the amount forgiven will be recorded as income or (2) the Company pays off the loan.</span><span style="background-color:#ffffff;color:#424242;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021 and was included in other income in the unaudited condensed consolidated income statement for the three-month period ended September 30, 2021.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenues </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plans for a 12-month period. The consideration received is recognized monthly over the service period. </span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:35.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.757%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (Loss) earnings Per Share</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Loss) earnings per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of September 30, 2022, and 2021, the average market prices for the three-month periods then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three-month periods ended September 30, 2022. Therefore, basic and diluted loss per common share for the three-month periods ended September 30, 2022 are the same. </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.970%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.247%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Numerator for basic loss per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Net (loss) income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320,724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income applicable to common shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,730)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for diluted earnings per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income applicable to common shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted (loss) income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320,724)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic (loss) earnings per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic (loss) earnings per share - weighted average shares outstanding<br/></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average preferred stock converted to common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,460,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Denominator for diluted (loss) earnings assumed conversion</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,876,202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) earnings per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) earnings per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) earnings per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.05)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.</span></div> <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:27.772%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.789%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,891,580 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive securities not included in income per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,048,580</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of September 30, 2022 and June 30, 2022, the Company has a fully recorded valuation allowance against its deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of September 30, 2022 and June 30, 2022, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited condensed consolidated balance sheets.</span></div> The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company recorded an allowance for doubtful accounts of approximately $241,000 and $236,000 as of September 30, 2022 and June 30, 2022, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span> 241000 236000 Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the Company’s forecasts of future sales and age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely impact the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year. <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's policy is to account for the PPP loan</span><span style="background-color:#ffffff;color:#001f5e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(See Note 7)</span><span style="background-color:#ffffff;color:#001f5e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as debt. The Company will continue to record the loan as debt until either (1) the loan is partially or entirely forgiven and the Company has been legally released</span><span style="background-color:#ffffff;color:#001f5e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at which point the amount forgiven will be recorded as income or (2) the Company pays off the loan.</span><span style="background-color:#ffffff;color:#424242;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021 and was included in other income in the unaudited condensed consolidated income statement for the three-month period ended September 30, 2021.</span> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenues </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plans for a 12-month period. The consideration received is recognized monthly over the service period. </span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:35.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.757%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:35.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.757%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 332000 364000 104000 107000 162000 195000 274000 276000 (Loss) earnings per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of September 30, 2022, and 2021, the average market prices for the three-month periods then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three-month periods ended September 30, 2022. Therefore, basic and diluted loss per common share for the three-month periods ended September 30, 2022 are the same. <div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.970%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.247%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Numerator for basic loss per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Net (loss) income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320,724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income applicable to common shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,730)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for diluted earnings per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income applicable to common shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted (loss) income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320,724)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic (loss) earnings per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic (loss) earnings per share - weighted average shares outstanding<br/></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average preferred stock converted to common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,460,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Denominator for diluted (loss) earnings assumed conversion</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,876,202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) earnings per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) earnings per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) earnings per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.05)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.</span></div> <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:27.772%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.789%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,891,580 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive securities not included in income per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,048,580</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of September 30, 2022 and June 30, 2022, the Company has a fully recorded valuation allowance against its deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of September 30, 2022 and June 30, 2022, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited condensed consolidated balance sheets.</span></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.970%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.247%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Numerator for basic loss per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Net (loss) income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320,724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income applicable to common shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,730)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for diluted earnings per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income applicable to common shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted (loss) income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320,724)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic (loss) earnings per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic (loss) earnings per share - weighted average shares outstanding<br/></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average preferred stock converted to common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,460,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Denominator for diluted (loss) earnings assumed conversion</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,876,202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) earnings per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) earnings per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) earnings per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.05)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> -320724 -320724 -320724 317220 317220 317220 13006 13006 -333730 304214 -333730 304214 13006 13006 -320724 317220 7415329 7415329 7415329 7415329 0 5460873 7415329 12876202 -0.05 0.04 -0.05 0.02 The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share. <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:27.772%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.789%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,891,580 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive securities not included in income per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,048,580</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of September 30, 2022 and June 30, 2022, the Company has a fully recorded valuation allowance against its deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of September 30, 2022 and June 30, 2022, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited condensed consolidated balance sheets.</span></div> 157000 157000 157000 157000 5891580 5891580 0 0 6048580 6048580 157000 157000 Inventories <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.156%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Raw Material</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Work-In-Process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Finished Goods</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for obsolete inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.156%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Raw Material</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Work-In-Process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Finished Goods</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for obsolete inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1028000 1010000 154000 138000 785000 806000 1967000 1954000 350000 350000 1617000 1604000 Related Party Transactions and Preferred Stock    On February 14, 2018, the Company entered into a Debt Exchange Agreement (the “Exchange Agreement”) with Richard DePiano, Sr., (Mr. DePiano Sr.), the Company's former Chairman and DP Associates Inc. Profit-Sharing Plan of <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which Mr. DePiano Sr. is the sole owner and sole trustee (the “Holders”).  Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program the Company owes the Holders for 2,000,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders.  As a result of this voting power, the Holders as September 30, 2022 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company’s shareholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the “Conversion Ratio”).  The Conversion Ratio is subject to standard provisions for adjustment in the event of a subdivision or combination of the Company’s Common Stock and upon any reorganization or reclassification of the capital stock of the Company. If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the then outstanding shares of Common Stock assuming such conversion. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock. Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full. The dividends payable to the holders of the Preferred Stock is payable in cash or, at the election of any such holder, in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable Conversion Ratio, described above. As of September 30, 2022 and June 30, 2022 the cumulative dividends payable is $238,737 ($0.1194 per share) a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd $225,731 ($0.1129 per share), respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Mr. DePiano Sr. passed away on October 3, 2019 and left a will by which he appointed Richard J. DePiano, Jr., the Chief Executive Officer of the Company, as executor. Richard DePiano Jr. was elected to serve as chairman of the Company's board. Mr. DePiano, Jr. qualified as executor and has control over the listed shares in his capacity as executor of Mr. DePiano Sr.'s estate.</span></div> 645000 2000000 77.81 2.15 4,300,000 0.3670 0.0258 238737 0.1194 225731 0.1129 On June 29, 2018 the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.0% per annum. Interest on the unpaid principal balance of the note is calculated using a rate of 0.74 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.74% per annum based on a year of 360 days. The interest rate was 6.54% as of September 30, 2022. The Company was required to put $250,000 in the TD bank savings account as collateral. The Loan is now guaranteed by Mr. DePiano Jr.     As of September 30, 2022 and June 30, 2022, the line of credit balance was $201,575 with TD bank. The line of credit interest expense was approximately $3,000 for the three months ended September 30, 2022 and 2021, respectively. 250000 0.050 0.74 0.0574 0.0654 250000 201575 3000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paycheck Protection Program ("PPP") loan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">    On April 27, 2020, the Company entered into a PPP loan for $500,000 in connection with the CARES Act related to COVID-19. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The full amount of the PPP loan and accrued interest were forgiven on August 13, 2021 a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">nd was included in other income in the unaudited condensed consolidated statement of operations for the three-month period ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic Injury Disaster ("EIDL") Loan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received a $150,000 EIDL loan. The annual interest rate is 3.75%. The payment term is 30 years and the monthly payment of $731 started on July 1st, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The future annual principal amounts to be paid as of September 30, 2022 are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:34.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:63.400%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending June 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EIDL Payment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder of FY 2023)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,157 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other short-term Liabilities</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The CARES Act allows employers to defer the deposit and payment of the employer share of Social Security tax that </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would otherwise be due on or after March 27, 2020, and before January 1, 2021. The Company had deferred approximately $82,000</span> of the social security tax. 50% of the deferred employment taxes was paid before December 31, 2021. The remaining 50% is not due until December 31, 2022. Approximately $41,000 was reported as short-term other liabilities as of September 30, 2022. 500000 150000 150000 0.0375 731 The future annual principal amounts to be paid as of September 30, 2022 are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:34.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:63.400%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending June 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EIDL Payment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder of FY 2023)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,157 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:34.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:63.400%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending June 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EIDL Payment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder of FY 2023)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,157 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table> 2631 3237 3376 3497 139416 152157 82000 41000 <div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely address the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Major Customer</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    No customer accounted for more than 10% of net sales during the three-month period ended September 30, 2022. One customer accounted for 13% during the three-month period ended September 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of September 30, 2022 the Company had one customer that represented 11% of the total accounts receivable balance. As of June 30, 2022 the Company had one customer that represents 13% of the total accounts receivable balance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Major Supplier</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's one largest supplier accounted for 38% of the total purchase for the three-month period ended September 30, 2022. The Company's three largest suppliers accounted for 32%, 13% and 11% of total purchases for the three-month period ended September 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of September 30, 2022 the Company had two supplier that represented 33% and 13% of the total accounts payable balance. As of June 30, 2022 the Company had one suppliers that represent approximately 36% of the total accounts payable balance.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregated Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Domestic and international sales from operations are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.552%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">( in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,620 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,605 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> No One 0.13 one 0.11 one 0.13 one 0.38 three 0.32 0.13 0.11 two 0.33 0.13 one 0.36 Domestic and international sales from operations are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.552%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">( in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,620 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,605 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 0.622 1625000 1625000 0.607 985000 0.378 1050000 0.393 2605000 1 2675000 2675000 1 Leases<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company leases certain facilities and equipment under operating leases. Total lease expense, under ASC 842, was included in cost of goods sold and marketing, general and administrative costs in our unaudited condensed consolidated statements of operations for the three months ended September 30, 2022 and 2021 as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"/><td style="width:42.138%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease costs:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,436 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,245 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Supplemental cash flow information was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:45.666%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.414%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, </span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,592 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,390 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheets as of September 30, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:68.561%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (reminder of FY 2023)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822,734 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less interest </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770,112 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Average lease terms and discount rates were as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease terms (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.61</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"/><td style="width:42.138%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease costs:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,436 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,245 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:45.666%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.414%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, </span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,592 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,390 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease terms (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.61</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 85436 84245 85436 84245 84592 82390 84592 82390 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:68.561%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (reminder of FY 2023)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822,734 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less interest </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770,112 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 258649 350142 211215 2728 822734 52622 770112 P2Y4M9D P2Y7M9D 0.0565 0.0565 EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 76 186 1 false 25 0 false 4 false false R1.htm 0000001 - Document - Cover Sheet http://www.escalonmed.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Consolidated Balance Sheets Sheet http://www.escalonmed.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Consolidated Statements Of Operations Sheet http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations Consolidated Statements Of Operations Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements Of Shareholders' Equity and Comprehensive Loss Sheet http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss Consolidated Statements Of Shareholders' Equity and Comprehensive Loss Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements Of Cash Flows Sheet http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements Of Cash Flows Statements 6 false false R7.htm 0000007 - Disclosure - Organization and Description of Business Sheet http://www.escalonmed.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 7 false false R8.htm 0000008 - Disclosure - Going concern (Notes) Notes http://www.escalonmed.com/role/GoingconcernNotes Going concern (Notes) Notes 8 false false R9.htm 0000009 - Disclosure - Significant Accounting Policies Sheet http://www.escalonmed.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Inventory (Notes) Notes http://www.escalonmed.com/role/InventoryNotes Inventory (Notes) Notes 10 false false R11.htm 0000011 - Disclosure - Long term debt (Notes) Notes http://www.escalonmed.com/role/LongtermdebtNotes Long term debt (Notes) Notes 11 false false R12.htm 0000012 - Disclosure - Related Party Transactions Sheet http://www.escalonmed.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 0000013 - Disclosure - Line of credit (Notes) Notes http://www.escalonmed.com/role/LineofcreditNotes Line of credit (Notes) Notes 13 false false R14.htm 0000014 - Disclosure - Concentration of credit risk (Notes) Notes http://www.escalonmed.com/role/ConcentrationofcreditriskNotes Concentration of credit risk (Notes) Notes 14 false false R15.htm 0000015 - Disclosure - Leases (Notes) Notes http://www.escalonmed.com/role/LeasesNotes Leases (Notes) Notes 15 false false R16.htm 0000016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.escalonmed.com/role/SignificantAccountingPolicies 16 false false R17.htm 0000018 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.escalonmed.com/role/SignificantAccountingPolicies 17 false false R18.htm 0000019 - Disclosure - Inventory (Tables) Sheet http://www.escalonmed.com/role/InventoryTables Inventory (Tables) Tables http://www.escalonmed.com/role/InventoryNotes 18 false false R19.htm 0000020 - Disclosure - Long term debt (Tables) Sheet http://www.escalonmed.com/role/LongtermdebtTables Long term debt (Tables) Tables http://www.escalonmed.com/role/LongtermdebtNotes 19 false false R20.htm 0000021 - Disclosure - Concentration of credit risk (Tables) Sheet http://www.escalonmed.com/role/ConcentrationofcreditriskTables Concentration of credit risk (Tables) Tables http://www.escalonmed.com/role/ConcentrationofcreditriskNotes 20 false false R21.htm 0000022 - Disclosure - Leases (Tables) Sheet http://www.escalonmed.com/role/LeasesTables Leases (Tables) Tables http://www.escalonmed.com/role/LeasesNotes 21 false false R22.htm 0000024 - Disclosure - Going concern (Details) Sheet http://www.escalonmed.com/role/GoingconcernDetails Going concern (Details) Details http://www.escalonmed.com/role/GoingconcernNotes 22 false false R23.htm 0000025 - Disclosure - Significant Accounting Policies (Cash and Cash Equivalents) (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails Significant Accounting Policies (Cash and Cash Equivalents) (Details) Details http://www.escalonmed.com/role/SignificantAccountingPoliciesTables 23 false false R24.htm 0000026 - Disclosure - Significant Accounting Policies (Inventory) (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails Significant Accounting Policies (Inventory) (Details) Details http://www.escalonmed.com/role/SignificantAccountingPoliciesTables 24 false false R25.htm 0000027 - Disclosure - Significant Accounting Policies (Accounts Receivable) (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails Significant Accounting Policies (Accounts Receivable) (Details) Details http://www.escalonmed.com/role/SignificantAccountingPoliciesTables 25 false false R26.htm 0000028 - Disclosure - Significant Accounting Policies (Net Income (loss) Per Share) (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails Significant Accounting Policies (Net Income (loss) Per Share) (Details) Details http://www.escalonmed.com/role/SignificantAccountingPoliciesTables 26 false false R27.htm 0000029 - Disclosure - Significant Accounting Policies Earning per share details (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails Significant Accounting Policies Earning per share details (Details) Details 27 false false R28.htm 0000032 - Disclosure - Significant Accounting Policies deferred revenue (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails Significant Accounting Policies deferred revenue (Details) Details 28 false false R29.htm 0000033 - Disclosure - Significant Accounting Policies New accounting pronouncements recently adopted (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesNewaccountingpronouncementsrecentlyadoptedDetails Significant Accounting Policies New accounting pronouncements recently adopted (Details) Details 29 false false R30.htm 0000034 - Disclosure - Inventory (Details) Sheet http://www.escalonmed.com/role/InventoryDetails Inventory (Details) Details http://www.escalonmed.com/role/InventoryTables 30 false false R31.htm 0000035 - Disclosure - Long term debt (Details) Sheet http://www.escalonmed.com/role/LongtermdebtDetails Long term debt (Details) Details http://www.escalonmed.com/role/LongtermdebtTables 31 false false R32.htm 0000036 - Disclosure - Related Party Transactions (Details) Sheet http://www.escalonmed.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.escalonmed.com/role/RelatedPartyTransactions 32 false false R33.htm 0000037 - Disclosure - Line of credit (Details) Sheet http://www.escalonmed.com/role/LineofcreditDetails Line of credit (Details) Details http://www.escalonmed.com/role/LineofcreditNotes 33 false false R34.htm 0000038 - Disclosure - Concentration of credit risk (Details) Sheet http://www.escalonmed.com/role/ConcentrationofcreditriskDetails Concentration of credit risk (Details) Details http://www.escalonmed.com/role/ConcentrationofcreditriskTables 34 false false R35.htm 0000039 - Disclosure - Leases (Details) Sheet http://www.escalonmed.com/role/LeasesDetails Leases (Details) Details http://www.escalonmed.com/role/LeasesTables 35 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 24 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentPeriodEndDate, dei:DocumentQuarterlyReport, dei:DocumentTransitionReport, dei:DocumentType, dei:EntityCommonStockSharesOutstanding, dei:EntityEmergingGrowthCompany, dei:EntityFileNumber, dei:EntityRegistrantName, dei:EntityShellCompany, dei:EntitySmallBusiness, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued - esmc-20220930.htm 4 esmc-20220930.htm esmc-20220930.xsd esmc-20220930_cal.xml esmc-20220930_def.xml esmc-20220930_lab.xml esmc-20220930_pre.xml esmc_2022930-10qex311.htm esmc_2022930-10qex312.htm esmc_2022930-10qex321.htm esmc_2022930-10qex322.htm http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 53 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "esmc-20220930.htm": { "axisCustom": 0, "axisStandard": 10, "contextCount": 76, "dts": { "calculationLink": { "local": [ "esmc-20220930_cal.xml" ] }, "definitionLink": { "local": [ "esmc-20220930_def.xml" ] }, "inline": { "local": [ "esmc-20220930.htm" ] }, "labelLink": { "local": [ "esmc-20220930_lab.xml" ] }, "presentationLink": { "local": [ "esmc-20220930_pre.xml" ] }, "schema": { "local": [ "esmc-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 324, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 14, "http://xbrl.sec.gov/dei/2022": 15, "total": 29 }, "keyCustom": 5, "keyStandard": 181, "memberCustom": 7, "memberStandard": 17, "nsprefix": "esmc", "nsuri": "http://www.escalonmed.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "role": "http://www.escalonmed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Inventory (Notes)", "role": "http://www.escalonmed.com/role/InventoryNotes", "shortName": "Inventory (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Long term debt (Notes)", "role": "http://www.escalonmed.com/role/LongtermdebtNotes", "shortName": "Long term debt (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Related Party Transactions", "role": "http://www.escalonmed.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Line of credit (Notes)", "role": "http://www.escalonmed.com/role/LineofcreditNotes", "shortName": "Line of credit (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Concentration of credit risk (Notes)", "role": "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes", "shortName": "Concentration of credit risk (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Leases (Notes)", "role": "http://www.escalonmed.com/role/LeasesNotes", "shortName": "Leases (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Inventory (Tables)", "role": "http://www.escalonmed.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Long term debt (Tables)", "role": "http://www.escalonmed.com/role/LongtermdebtTables", "shortName": "Long term debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "iedaa701c12134079ad82e66bc5c7a441_I20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Consolidated Balance Sheets", "role": "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "iedaa701c12134079ad82e66bc5c7a441_I20220930", "decimals": "0", "lang": "en-US", "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Concentration of credit risk (Tables)", "role": "http://www.escalonmed.com/role/ConcentrationofcreditriskTables", "shortName": "Concentration of credit risk (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R21": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Leases (Tables)", "role": "http://www.escalonmed.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "iedaa701c12134079ad82e66bc5c7a441_I20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Going concern (Details)", "role": "http://www.escalonmed.com/role/GoingconcernDetails", "shortName": "Going concern (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "iedaa701c12134079ad82e66bc5c7a441_I20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Significant Accounting Policies (Cash and Cash Equivalents) (Details)", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails", "shortName": "Significant Accounting Policies (Cash and Cash Equivalents) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "iedaa701c12134079ad82e66bc5c7a441_I20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:InventoryNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Significant Accounting Policies (Inventory) (Details)", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails", "shortName": "Significant Accounting Policies (Inventory) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R25": { "firstAnchor": { "ancestors": [ "span", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "if5c5b75abb3740179d6f389f287843bf_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Significant Accounting Policies (Accounts Receivable) (Details)", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails", "shortName": "Significant Accounting Policies (Accounts Receivable) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "if5c5b75abb3740179d6f389f287843bf_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Significant Accounting Policies (Net Income (loss) Per Share) (Details)", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails", "shortName": "Significant Accounting Policies (Net Income (loss) Per Share) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Significant Accounting Policies Earning per share details (Details)", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "shortName": "Significant Accounting Policies Earning per share details (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": "0", "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "iedaa701c12134079ad82e66bc5c7a441_I20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Significant Accounting Policies deferred revenue (Details)", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails", "shortName": "Significant Accounting Policies deferred revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "div", "us-gaap:RevenueRecognitionPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "iaa7fe17ccdcd4026a12f80a055768a02_I20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "iedaa701c12134079ad82e66bc5c7a441_I20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Significant Accounting Policies New accounting pronouncements recently adopted (Details)", "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesNewaccountingpronouncementsrecentlyadoptedDetails", "shortName": "Significant Accounting Policies New accounting pronouncements recently adopted (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "iedaa701c12134079ad82e66bc5c7a441_I20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:InventoryNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Inventory (Details)", "role": "http://www.escalonmed.com/role/InventoryDetails", "shortName": "Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "iedaa701c12134079ad82e66bc5c7a441_I20220930", "decimals": "0", "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Long term debt (Details)", "role": "http://www.escalonmed.com/role/LongtermdebtDetails", "shortName": "Long term debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "ia0f62082101d4589afcabbe5f89859ed_I20180214", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionDueFromToRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Related Party Transactions (Details)", "role": "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "ia0f62082101d4589afcabbe5f89859ed_I20180214", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionDueFromToRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityPeriodicPaymentInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Line of credit (Details)", "role": "http://www.escalonmed.com/role/LineofcreditDetails", "shortName": "Line of credit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityPeriodicPaymentInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Concentration of credit risk (Details)", "role": "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "shortName": "Concentration of credit risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "ic4eaad3eb5ca4f5e963e3219a138f4b8_D20220701-20220930", "decimals": null, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCustomer", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShortTermLeasePayments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Leases (Details)", "role": "http://www.escalonmed.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "iedaa701c12134079ad82e66bc5c7a441_I20220930", "decimals": "0", "lang": "en-US", "name": "esmc:Netpresentvalueofnewleasefuturepayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Statements Of Operations", "role": "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements Of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i2bb6060393dd4cb7bb84155176634e34_D20220701-20220930", "decimals": "0", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i1a9c350c7e854902b58a9888a7fbc8f0_I20210630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Statements Of Shareholders' Equity and Comprehensive Loss", "role": "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss", "shortName": "Consolidated Statements Of Shareholders' Equity and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i1a9c350c7e854902b58a9888a7fbc8f0_I20210630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Statements Of Cash Flows", "role": "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements Of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": "0", "lang": "en-US", "name": "us-gaap:ProvisionForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - Organization and Description of Business", "role": "http://www.escalonmed.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Going concern (Notes)", "role": "http://www.escalonmed.com/role/GoingconcernNotes", "shortName": "Going concern (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Significant Accounting Policies", "role": "http://www.escalonmed.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "esmc-20220930.htm", "contextRef": "i17c078d6e2544955b5fe649c78d892c0_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 25, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "Domestic [Member]" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "esmc_AccountsPayableBenchmarkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Payable Benchmark [Member]", "label": "Accounts Payable Benchmark [Member]", "terseLabel": "Accounts Payable Benchmark [Member]" } } }, "localname": "AccountsPayableBenchmarkMember", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "esmc_AccountsReceivableBenchmarkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Receivable Benchmark [Member]", "label": "Accounts Receivable Benchmark [Member]", "terseLabel": "Accounts Receivable Benchmark [Member]" } } }, "localname": "AccountsReceivableBenchmarkMember", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "esmc_ConcentrationofcreditrisksAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration of credit risks [Abstract]", "label": "Concentration of credit risks [Abstract]", "terseLabel": "Concentration of credit risks [Abstract]" } } }, "localname": "ConcentrationofcreditrisksAbstract", "nsuri": "http://www.escalonmed.com/20220930", "xbrltype": "stringItemType" }, "esmc_ConvertiblePreferredStockPercentageOfOutstandingSharesOfCommonStockUponConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion", "label": "Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion", "terseLabel": "Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion" } } }, "localname": "ConvertiblePreferredStockPercentageOfOutstandingSharesOfCommonStockUponConversion", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "esmc_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer One [Member]", "label": "Customer One [Member]", "terseLabel": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "domainItemType" }, "esmc_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Two [Member]", "label": "Customer Two [Member]", "terseLabel": "Customer Two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "esmc_DisposeLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "DisposeLeaseLiabilities", "label": "DisposeLeaseLiabilities", "terseLabel": "DisposeLeaseLiabilities" } } }, "localname": "DisposeLeaseLiabilities", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "esmc_DisposeROUassets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "DisposeROUassets", "label": "DisposeROUassets", "terseLabel": "DisposeROUassets" } } }, "localname": "DisposeROUassets", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "esmc_EIDLLoanAndAccruedInterest": { "auth_ref": [], "calculation": { "http://www.escalonmed.com/role/LongtermdebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "EIDL Loan and Accrued Interest", "label": "EIDL loan and accrued interest", "totalLabel": "Long-term Debt" } } }, "localname": "EIDLLoanAndAccruedInterest", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "esmc_EIDLMonthlyPaymentincludingPrincipalandInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "MonthlyFixedPayment", "label": "EIDL Monthly Payment including Principal and Interest", "terseLabel": "EIDL Monthly Payment including Principal and Interest" } } }, "localname": "EIDLMonthlyPaymentincludingPrincipalandInterest", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "esmc_EarningpershareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earning per share [Abstract]", "label": "Earning per share [Abstract]", "terseLabel": "Earning per share [Abstract]" } } }, "localname": "EarningpershareAbstract", "nsuri": "http://www.escalonmed.com/20220930", "xbrltype": "stringItemType" }, "esmc_GoingconcernAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Going concern [Abstract]", "label": "Going concern [Abstract]", "terseLabel": "Going concern [Abstract]" } } }, "localname": "GoingconcernAbstract", "nsuri": "http://www.escalonmed.com/20220930", "xbrltype": "stringItemType" }, "esmc_Interestportioninthefutureleasepayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest portion in the future lease payments", "label": "Interest portion in the future lease payments", "terseLabel": "Interest portion in the future lease payments" } } }, "localname": "Interestportioninthefutureleasepayments", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "esmc_MaximumMaturityOfHighlyLiquidInvestmentsPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum maturity of highly liquid investments, period.", "label": "Maximum Maturity of Highly Liquid Investments, Period", "terseLabel": "Maximum maturity of highly liquid investments, period" } } }, "localname": "MaximumMaturityOfHighlyLiquidInvestmentsPeriod", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails" ], "xbrltype": "durationItemType" }, "esmc_Netpresentvalueofnewleasefuturepayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net present value of new lease future payments", "label": "Net present value of new lease future payments", "terseLabel": "Net present value of new lease future payments" } } }, "localname": "Netpresentvalueofnewleasefuturepayments", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "esmc_NewaccountingpronouncementsrecentlyadoptedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New accounting pronouncements recently adopted [Abstract]", "label": "New accounting pronouncements recently adopted [Abstract]", "terseLabel": "New accounting pronouncements recently adopted [Abstract]" } } }, "localname": "NewaccountingpronouncementsrecentlyadoptedAbstract", "nsuri": "http://www.escalonmed.com/20220930", "xbrltype": "stringItemType" }, "esmc_PPPloanamount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "PPP loan amount", "label": "PPP loan amount", "terseLabel": "PPP loan amount" } } }, "localname": "PPPloanamount", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "esmc_PayrollProtectionProgramLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payroll Protection Program Loan [Member]", "label": "Payroll Protection Program Loan [Member]", "terseLabel": "Payroll Protection Program Loan [Member]" } } }, "localname": "PayrollProtectionProgramLoanMember", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "domainItemType" }, "esmc_RecordLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Record lease liabilities", "terseLabel": "Record lease liabilities" } } }, "localname": "RecordLeaseLiabilities", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "esmc_RecordROUassets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "RecordROUassets", "label": "RecordROUassets", "terseLabel": "RecordROUassets" } } }, "localname": "RecordROUassets", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "esmc_RepaymentOfEIDLLoan": { "auth_ref": [], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment of EIDL loan", "label": "Repayment of EIDL loan", "negatedTerseLabel": "Repayment of EIDL loan" } } }, "localname": "RepaymentOfEIDLLoan", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "esmc_ScheduleofinventoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "schedule of inventory [Abstract]", "label": "schedule of inventory [Abstract]", "terseLabel": "schedule of inventory [Abstract]" } } }, "localname": "ScheduleofinventoryAbstract", "nsuri": "http://www.escalonmed.com/20220930", "xbrltype": "stringItemType" }, "esmc_SupplierTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplier two", "label": "Supplier two [Member]", "terseLabel": "Supplier two [Member]" } } }, "localname": "SupplierTwoMember", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "esmc_SupplieroneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplier one [Member]", "label": "Supplier one [Member]", "terseLabel": "Supplier one [Member]" } } }, "localname": "SupplieroneMember", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "esmc_SupplierthreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplier three [Member]", "label": "Supplier three [Member]", "terseLabel": "Supplier three [Member]" } } }, "localname": "SupplierthreeMember", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "esmc_WisconsinWarehouseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wisconsin Warehouse", "label": "Wisconsin Warehouse [Member]", "terseLabel": "Wisconsin Warehouse" } } }, "localname": "WisconsinWarehouseMember", "nsuri": "http://www.escalonmed.com/20220930", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Contractual Obligation, Fiscal Year Maturity" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtTables" ], "xbrltype": "textBlockItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r48", "r50", "r91", "r92", "r217", "r250", "r417" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Domain]", "terseLabel": "Equity Method Investee, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r164", "r263", "r266", "r379" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r164", "r263", "r266", "r379" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r161", "r194", "r195", "r263", "r264", "r350", "r375", "r377" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r161", "r194", "r195", "r263", "r264", "r350", "r375", "r377" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r192", "r193", "r194", "r195", "r196", "r216", "r249", "r267", "r268", "r269", "r270", "r271", "r272", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r376", "r380", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r192", "r193", "r194", "r195", "r196", "r216", "r249", "r267", "r268", "r269", "r270", "r271", "r272", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r376", "r380", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r49", "r50", "r91", "r92", "r217", "r250" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Axis]", "terseLabel": "Equity Method Investee, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r162", "r163", "r263", "r265", "r378", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r162", "r163", "r263", "r265", "r378", "r387", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r407", "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r38", "r339" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r165", "r166" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r22", "r339" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r95", "r96", "r97", "r273", "r274", "r275", "r292" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r27", "r171", "r179", "r180", "r182" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Accounts Receivable, Allowance for Credit Loss" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r13", "r89", "r150", "r153", "r159", "r177", "r200", "r201", "r202", "r204", "r205", "r206", "r207", "r208", "r209", "r211", "r212", "r285", "r288", "r300", "r337", "r339", "r353", "r366" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r36", "r89", "r177", "r200", "r201", "r202", "r204", "r205", "r206", "r207", "r208", "r209", "r211", "r212", "r285", "r288", "r300", "r337", "r339" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r11", "r77" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r71", "r77", "r81" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, End of Period", "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning of Period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r71", "r301" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockConversionBasis": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Description of basis for conversion of convertible common stock.", "label": "Common Stock, Conversion Basis", "terseLabel": "Common Stock, Conversion Basis" } } }, "localname": "CommonStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r95", "r96", "r292" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r21", "r339" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Common Stock, Voting Rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r137", "r138", "r164", "r297", "r298", "r388" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes", "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r137", "r138", "r164", "r297", "r298", "r386", "r388" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes", "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r137", "r138", "r164", "r297", "r298", "r386", "r388" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes", "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCustomer": { "auth_ref": [ "r134", "r135", "r138" ], "lang": { "en-us": { "role": { "documentation": "Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes \"Information about Major Customers\" that may be disclosed elsewhere (for instance, segment disclosures).", "label": "Concentration Risk, Customer", "terseLabel": "Concentration Risk, Customer" } } }, "localname": "ConcentrationRiskCustomer", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentration Risk Disclosure [Text Block]" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r137", "r138", "r164", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows", "http://www.escalonmed.com/role/LineofcreditDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskSupplier": { "auth_ref": [ "r134", "r135", "r138", "r143" ], "lang": { "en-us": { "role": { "documentation": "Description of risks that arise due to the volume of business transacted with a particular supplier or reliance placed on that supplier. At a minimum, the description informs financial statement users of the general nature of the risk.", "label": "Concentration Risk, Supplier", "terseLabel": "Concentration Risk, Supplier" } } }, "localname": "ConcentrationRiskSupplier", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r134", "r137", "r138", "r139", "r297", "r299", "r388" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r137", "r138", "r164", "r297", "r298", "r388" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes", "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r83", "r287" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertiblePreferredDividendsNetOfTax": { "auth_ref": [ "r109", "r110", "r112", "r122", "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The after-tax amount of any dividends on convertible preferred stock.", "label": "Convertible Preferred Dividends, Net of Tax", "terseLabel": "Convertible Preferred Dividends, Net of Tax" } } }, "localname": "ConvertiblePreferredDividendsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r247", "r248", "r251" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r19", "r20", "r253", "r255", "r257" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Convertible Preferred Stock, Shares Issued upon Conversion" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss", "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r63", "r350" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Goods and Services Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsTotalMember": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation.", "label": "Cost of Goods and Service Benchmark [Member]", "terseLabel": "Cost of Goods and Service Benchmark" } } }, "localname": "CostOfGoodsTotalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r62" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "terseLabel": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofcreditNotes" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofcreditNotes" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r135", "r164" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r87", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r230", "r237", "r238", "r240", "r246" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofcreditNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r88", "r93", "r213", "r214", "r215", "r216", "r217", "r218", "r220", "r226", "r227", "r228", "r229", "r231", "r232", "r233", "r234", "r235", "r236", "r242", "r243", "r244", "r245", "r314", "r354", "r355", "r365" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r44", "r233", "r312" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Debt Instrument, Interest Rate During Period" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r44", "r214" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r45", "r88", "r93", "r213", "r214", "r215", "r216", "r217", "r218", "r220", "r226", "r227", "r228", "r229", "r231", "r232", "r233", "r234", "r235", "r236", "r242", "r243", "r244", "r245", "r314" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r45", "r362" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Debt Instrument, Periodic Payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r45", "r88", "r93", "r213", "r214", "r215", "r216", "r217", "r218", "r220", "r226", "r227", "r228", "r229", "r231", "r232", "r233", "r234", "r235", "r236", "r239", "r242", "r243", "r244", "r245", "r255", "r258", "r259", "r260", "r311", "r312", "r314", "r315", "r364" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r18" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.", "label": "Deferred Revenue, Additions", "terseLabel": "Deferred Revenue, Additions" } } }, "localname": "DeferredRevenueAdditions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.", "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]", "terseLabel": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]" } } }, "localname": "DeferredRevenueByArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Revenue Recognized", "terseLabel": "Deferred Revenue, Revenue Recognized" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r12" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "terseLabel": "Deposits Assets, Noncurrent" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r75", "r149" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.", "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities", "terseLabel": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities" } } }, "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableAmountPerShare": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.", "label": "Dividends Payable, Amount Per Share", "negatedTerseLabel": "Dividends Payable, Amount Per Share" } } }, "localname": "DividendsPayableAmountPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income (loss) per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r60", "r100", "r101", "r102", "r103", "r104", "r108", "r111", "r120", "r121", "r122", "r125", "r126", "r293", "r294", "r358", "r374" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Earnings (Loss) Per Share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r60", "r100", "r101", "r102", "r103", "r104", "r111", "r120", "r121", "r122", "r125", "r126", "r293", "r294", "r358", "r374" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings (Loss) Per Share, Diluted", "verboseLabel": "Earnings (Loss) Per Share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r123", "r124" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r54", "r55", "r56", "r95", "r96", "r97", "r99", "r105", "r107", "r128", "r178", "r254", "r261", "r273", "r274", "r275", "r283", "r284", "r292", "r302", "r303", "r304", "r305", "r306", "r307", "r329", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Total Shareholders' Equity [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity Method Investment, Ownership Percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r189", "r351" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Finite-Lived Intangible Assets, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r136", "r388" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r187", "r188" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r75", "r190" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill)" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesGoodwillandintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r53", "r277", "r278", "r279", "r280", "r281", "r282" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r74" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Increase (Decrease) in Accounts Payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r74" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Increaser(Decrease) in Accounts Receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r74" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Increase (Decrease) in Accrued Liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r74" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Increase (Decrease) in Deferred Revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r74" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Increase (Decrease) in Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r74" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Increase (Decrease) in Other Deferred Liability" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r74" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedTerseLabel": "Increase (Decrease) in Other Operating Assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r74" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Increase (Decrease) in Other Operating Liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "auth_ref": [ "r116", "r117", "r122" ], "calculation": { "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock", "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InformationByCategoryOfDebtSecurityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.", "label": "Debt Security Category [Axis]", "terseLabel": "Debt Security Category [Axis]" } } }, "localname": "InformationByCategoryOfDebtSecurityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r57", "r148", "r310", "r313", "r359" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r70", "r72", "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest Paid, Excluding Capitalized Interest, Operating Activities" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Interest Payable, Current" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory Disclosure [Text Block]" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/InventoryNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r28" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Inventory, Finished Goods, Gross" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "terseLabel": "Inventory, Gross" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r34", "r339" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/InventoryDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r7", "r32", "r84", "r127", "r183", "r184", "r186", "r348" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Inventory, Raw Materials, Gross" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r34", "r185" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedTerseLabel": "Inventory Valuation Reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Inventory, Work in Process, Gross" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r65", "r147" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]" } } }, "localname": "LesseeDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r326" ], "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Operating Leases, Future Minimum Payments Due" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r326" ], "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r326" ], "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "Finance Lease, Liability, to be Paid, Year Five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r326" ], "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Finance Lease, Liability, to be Paid, Year Four" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r326" ], "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Finance Lease, Liability, to be Paid, Year Three" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r326" ], "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Finance Lease, Liability, to be Paid, Year Two" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lease" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r41", "r89", "r154", "r177", "r200", "r201", "r202", "r205", "r206", "r207", "r208", "r209", "r211", "r212", "r286", "r288", "r289", "r300", "r337", "r338" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r26", "r89", "r177", "r300", "r339", "r356", "r371" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r6", "r43", "r89", "r177", "r200", "r201", "r202", "r205", "r206", "r207", "r208", "r209", "r211", "r212", "r286", "r288", "r289", "r300", "r337", "r338", "r339" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r8", "r9", "r10", "r16", "r17", "r89", "r177", "r200", "r201", "r202", "r205", "r206", "r207", "r208", "r209", "r211", "r212", "r286", "r288", "r289", "r300", "r337", "r338" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r39", "r88" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofcreditDetails", "http://www.escalonmed.com/role/LineofcreditNotes" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Line of Credit Facility, Interest Rate at Period End" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r39", "r88" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofcreditDetails", "http://www.escalonmed.com/role/LineofcreditNotes" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofcreditDetails", "http://www.escalonmed.com/role/LineofcreditNotes" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityPeriodicPaymentInterest": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payment applied to interest.", "label": "Line of Credit Facility, Periodic Payment, Interest", "terseLabel": "Line of Credit Facility, Periodic Payment, Interest" } } }, "localname": "LineOfCreditFacilityPeriodicPaymentInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r39", "r88" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofcreditDetails", "http://www.escalonmed.com/role/LineofcreditNotes" ], "xbrltype": "stringItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r14", "r354" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line of Credit, Current", "terseLabel": "Line of credit" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoanCommitmentsPolicy": { "auth_ref": [ "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for loan commitments accounted for as derivatives, including the methods and assumptions used to estimate fair value and any associated hedging strategies.", "label": "Loan Commitments, Policy [Policy Text Block]", "terseLabel": "Loan Commitments, Policy" } } }, "localname": "LoanCommitmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r16", "r227", "r241", "r242", "r243", "r355", "r368" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Long-term Debt, Current Maturities" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r93", "r198", "r232" ], "calculation": { "http://www.escalonmed.com/role/LongtermdebtDetails": { "order": 6.0, "parentTag": "esmc_EIDLLoanAndAccruedInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Long-Term Debt, Maturity, after Year Five" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r93", "r198", "r232" ], "calculation": { "http://www.escalonmed.com/role/LongtermdebtDetails": { "order": 1.0, "parentTag": "esmc_EIDLLoanAndAccruedInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "Long-Term Debt, Maturity, Year One" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r93", "r198", "r232" ], "calculation": { "http://www.escalonmed.com/role/LongtermdebtDetails": { "order": 5.0, "parentTag": "esmc_EIDLLoanAndAccruedInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "Long-Term Debt, Maturity, Year Five" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r93", "r198", "r232" ], "calculation": { "http://www.escalonmed.com/role/LongtermdebtDetails": { "order": 4.0, "parentTag": "esmc_EIDLLoanAndAccruedInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "Long-Term Debt, Maturity, Year Four" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r93", "r198", "r232" ], "calculation": { "http://www.escalonmed.com/role/LongtermdebtDetails": { "order": 3.0, "parentTag": "esmc_EIDLLoanAndAccruedInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "Long-Term Debt, Maturity, Year Three" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r93", "r198", "r232" ], "calculation": { "http://www.escalonmed.com/role/LongtermdebtDetails": { "order": 2.0, "parentTag": "esmc_EIDLLoanAndAccruedInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "Long-Term Debt, Maturity, Year Two" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.", "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate", "terseLabel": "Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate" } } }, "localname": "LongTermDebtPercentageBearingFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-Term Debt [Text Block]", "terseLabel": "Long-term Debt [Text Block]" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LineofcreditDetails", "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r45", "r199" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LineofcreditDetails", "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.", "label": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time", "terseLabel": "Long-term Debt, Weighted Average Interest Rate, at Point in Time" } } }, "localname": "LongtermDebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r129", "r144" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Organization and Description of Business and Business Conditions" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r71" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by (Used in) Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Net Cash provided by (used in) Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r71" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Provided by (Used in) Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r71", "r73", "r76" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided by (Used in) Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r51", "r52", "r56", "r59", "r76", "r89", "r98", "r100", "r101", "r102", "r103", "r106", "r107", "r118", "r150", "r152", "r155", "r158", "r160", "r177", "r200", "r201", "r202", "r205", "r206", "r207", "r208", "r209", "r211", "r212", "r294", "r300", "r357", "r373" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net (loss) income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows", "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r100", "r101", "r102", "r103", "r108", "r109", "r119", "r122", "r150", "r152", "r155", "r158", "r160" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r110", "r112", "r113", "r114", "r115", "r119", "r122" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net Income (Loss) Available to Common Stockholders, Diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": { "auth_ref": [ "r109", "r122" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.", "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic", "terseLabel": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic" } } }, "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r66" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Nonoperating Income (Expense)", "totalLabel": "Total other (expense) income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBank": { "auth_ref": [ "r16", "r355", "r368" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, the carrying value as of the balance sheet date of notes payable to banks, excluding mortgage notes, initially due beyond one year or beyond the operating cycle if longer.", "label": "Notes Payable to Bank", "terseLabel": "Notes Payable to Bank" } } }, "localname": "NotesPayableToBank", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBanksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a bank.", "label": "Notes Payable to Banks [Member]", "terseLabel": "Notes Payable to Banks [Member]" } } }, "localname": "NotesPayableToBanksMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r150", "r152", "r155", "r158", "r160" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r322", "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r317" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating Lease, Liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r317" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating Lease, Liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r317" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating Lease, Liability, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r316" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LeasesDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNewaccountingpronouncementsrecentlyadoptedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r324", "r327" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r323", "r327" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r35", "r339" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other (expense) income:" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r42", "r339" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other short-term liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other Liabilities, Noncurrent" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebt": { "auth_ref": [ "r16", "r355", "r368" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other.", "label": "Other Long-Term Debt", "terseLabel": "Other Long-term Debt" } } }, "localname": "OtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermNotesPayable": { "auth_ref": [ "r45" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.", "label": "Other Notes Payable, Noncurrent", "terseLabel": "Other Notes Payable, Noncurrent" } } }, "localname": "OtherLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r76" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other Noncash Income (Expense)", "terseLabel": "us-gaap_OtherNonoperatingIncomeExpensenoncash" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r67" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other Nonoperating Income (Expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNotesPayableCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Other Notes Payable, Current", "terseLabel": "Other Notes Payable, Current" } } }, "localname": "OtherNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other Operating Activities, Cash Flow Statement" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherShortTermBorrowings": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.", "label": "Other Short-Term Borrowings", "terseLabel": "Other Short-term Borrowings" } } }, "localname": "OtherShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.", "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]", "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]" } } }, "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r68" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Payments to Acquire Intangible Assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockAmountOfPreferredDividendsInArrears": { "auth_ref": [ "r256" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of cumulative preferred dividends in arrears.", "label": "Preferred Stock, Amount of Preferred Dividends in Arrears", "terseLabel": "Dividends Payable, Date to be Paid" } } }, "localname": "PreferredStockAmountOfPreferredDividendsInArrears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "auth_ref": [], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.", "label": "Preferred Stock Dividends, Income Statement Impact", "terseLabel": "Preferred Stock Dividends, Income Statement Impact" } } }, "localname": "PreferredStockDividendsIncomeStatementImpact", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r20", "r247" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r20", "r247" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r20", "r339" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred Stock, Value, Issued", "verboseLabel": "Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized;2,000,000 issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r191", "r339", "r361", "r372" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r61", "r181" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Accounts Receivable, Credit Loss Expense (Reversal)" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": { "auth_ref": [ "r90", "r203", "r205", "r206", "r210", "r211", "r212", "r332" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Related Party Transaction, Due from (to) Related Party", "terseLabel": "Related Party Transaction, Due from (to) Related Party" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r330", "r331", "r332", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r69" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedTerseLabel": "Repayments of Notes Payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r276", "r349", "r400" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r11", "r81", "r352", "r369" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "verboseLabel": "Restricted Cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows", "http://www.escalonmed.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r11", "r81" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted Cash, Current" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r261", "r339", "r370", "r384", "r385" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "verboseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/GoingconcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r95", "r96", "r97", "r99", "r105", "r107", "r178", "r273", "r274", "r275", "r283", "r284", "r292", "r381", "r383" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r145", "r146", "r151", "r156", "r157", "r161", "r162", "r164", "r262", "r263", "r350" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition and Deferred Revenue [Abstract]", "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r85", "r86" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r58", "r89", "r145", "r146", "r151", "r156", "r157", "r161", "r162", "r164", "r177", "r200", "r201", "r202", "r205", "r206", "r207", "r208", "r209", "r211", "r212", "r300", "r360" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues", "totalLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r137", "r164" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/LineofcreditDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r7", "r31", "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/InventoryTables", "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt [Table Text Block]" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r81", "r352", "r369" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Restrictions on Cash and Cash Equivalents [Table Text Block]" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r134", "r137", "r138", "r139", "r297", "r299" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtCurrent": { "auth_ref": [ "r14", "r354", "r367" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt, Current", "terseLabel": "Secured Debt, Current" } } }, "localname": "SecuredDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt [Member]" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SecuredLongTermDebt": { "auth_ref": [ "r45" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.", "label": "Secured Long-Term Debt, Noncurrent", "terseLabel": "Secured Long-term Debt, Noncurrent" } } }, "localname": "SecuredLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r64" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Marketing, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by supplier.", "label": "Supplier [Axis]", "terseLabel": "Supplier [Axis]" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.", "label": "Supplier [Domain]", "terseLabel": "Supplier [Domain]" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "terseLabel": "Shares, Outstanding" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeasePayments": { "auth_ref": [ "r318" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability.", "label": "Short-Term Lease Payments", "terseLabel": "Short-term Lease Payments" } } }, "localname": "ShortTermLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails", "http://www.escalonmed.com/role/LeasesTables" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r82", "r94" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Accrued Warranties" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r47", "r54", "r55", "r56", "r95", "r96", "r97", "r99", "r105", "r107", "r128", "r178", "r254", "r261", "r273", "r274", "r275", "r283", "r284", "r292", "r302", "r303", "r304", "r305", "r306", "r307", "r329", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Statement, Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r95", "r96", "r97", "r128", "r350" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r21", "r24", "r25", "r89", "r173", "r177", "r300", "r339" ], "calculation": { "http://www.escalonmed.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets", "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r308", "r340" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r308", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r308", "r340" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "Liquidity Disclosure [Policy Text Block]" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/GoingconcernNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Schedule of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]", "terseLabel": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r167", "r168", "r169", "r170", "r172", "r174" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r130", "r131", "r132", "r133", "r140", "r141", "r142" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r110", "r122" ], "calculation": { "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "netLabel": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted average shares - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r108", "r122" ], "calculation": { "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares - basic", "verboseLabel": "Basic Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows", "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99380358&loc=d3e7102-108593" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r246": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496177-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.DD)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=116879480&loc=d3e417888-122833" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=116879480&loc=d3e417888-122833" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r309": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r336": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r401": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r402": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r403": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r404": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r405": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)" }, "r406": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r407": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r408": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r409": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r411": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r412": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r413": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r414": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r415": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r416": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r417": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" } }, "version": "2.1" } ZIP 54 0000862668-22-000026-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000862668-22-000026-xbrl.zip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end